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Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in death, usually
from respiratory failure, within 2–3 years of symptom onset. Non-invasive ventilation (NIV) is a treatment
that when given to patients in respiratory failure leads to improved survival and quality of life. Diaphragm
pacing (DP), using the NeuRx/4® diaphragm pacing system (DPS)™ (Synapse Biomedical, Oberlin, OH,
USA), is a new technique that may offer additional or alternative benefits to patients with ALS who are in
respiratory failure.
Objective: The Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis (DiPALS) trial evaluated
the effect of DP on survival over the study duration in patients with ALS with respiratory failure.
Design: The DiPALS trial was a multicentre, parallel-group, open-label, randomised controlled trial
incorporating health economic analyses and a qualitative longitudinal substudy.
Participants: Eligible participants had a diagnosis of ALS (ALS laboratory-supported probable, clinically
probable or clinically definite according to the World Federation of Neurology revised El Escorial criteria),
had been stabilised on riluzole for 30 days, were aged ≥ 18 years and were in respiratory failure. We
planned to recruit 108 patients from seven UK-based specialist ALS or respiratory centres. Allocation was
performed using 1 : 1 non-deterministic minimisation.
Interventions: Participants were randomised to either standard care (NIV alone) or standard care (NIV)
plus DP using the NeuRX/4 DPS.
Main outcome measures: The primary outcome was overall survival, defined as the time from
randomisation to death from any cause. Secondary outcomes were patient quality of life [assessed by
European Quality of Life-5 Dimensions, three levels (EQ-5D-3L), Short Form questionnaire-36 items
and Sleep Apnoea Quality of Life Index questionnaire]; carer quality of life (EQ-5D-3L and Caregiver Burden
Inventory); cost–utility analysis and health-care resource use; tolerability and adverse events. Acceptability
and attitudes to DP were assessed in a qualitative substudy.
Results: In total, 74 participants were randomised into the trial and analysed, 37 participants to NIV plus
pacing and 37 to standard care, before the Data Monitoring and Ethics Committee advised initial
suspension of recruitment (December 2013) and subsequent discontinuation of pacing (on safety grounds)
in all patients (June 2014). Follow-up assessments continued until the planned end of the study in
December 2014. The median survival (interquartile range) was 22.5 months (lower quartile 11.8 months;
upper quartile not reached) in the NIV arm and 11.0 months (6.7 to 17.0 months) in the NIV plus pacing
arm, with an adjusted hazard ratio of 2.27 (95% confidence interval 1.22 to 4.25; p= 0.01).
Conclusions: Diaphragmatic pacing should not be used as a routine treatment for patients with ALS in
respiratory failure.
Future work: It may be that certain population subgroups benefit from DP. We are unable to explain the
mechanism behind the excess mortality in the pacing arm, something the small trial size cannot help
address. Future research should investigate the mechanism by which harm or benefit occurs further.
Trial registration: Current Controlled Trials ISRCTN53817913.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 45.
See the HTA programme website for further project information. Additional funding was provided by the
Motor Neurone Disease Association of England, Wales and Northern Ireland.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xiii
List of figures xv
List of boxes xvii
List of abbreviations xix
Plain English summary xxi
Scientific summary xxiii
Chapter 1 Introduction 1
Management of amyotrophic lateral sclerosis 1
Evidence for diaphragm pacing in amyotrophic lateral sclerosis 1
Research objectives 2
Chapter 2 Methods 3
Trial design 3
Participants and eligibility criteria 3
Inclusion criteria 3
Exclusion criteria 4
Participant identification 4
Recruitment 4
Screening 5
Randomisation and blinding 5
Interventions 7
Non-invasive ventilation 7
Diaphragm pacing system 7
Surgical implantation 8
Evaluation of electrodes and diaphragm pacing system training 9
Outcomes 10
Primary outcome 10
Secondary outcomes 10
Follow-up visits 10
Data collection and management 10
Data collection forms 10
Database 10
Methods used for treatment allocation, sequence concealment and blinding 11
Sample size 11
Early stopping 12
Statistical methods 12
Survival 12
Quality of life 12
Non-invasive ventilation and diaphragm pacing usage 13
Health resource use 14
Additional outcomes: Amyotrophic Lateral Sclerosis Functional Rating Scale and
respiratory function 14
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix
Adverse events 14
General analysis considerations 14
Economic evaluation 15
Research governance 15
Sponsorship 15
Oversight committees 15
Research Ethics Committee 15
Medicines and Healthcare products Regulatory Agency 15
Serious adverse events 15
Protocol non-compliances 15
Monitoring and reporting 16
Important changes to methods after trial commencement 16
Patient and public involvement 18
Proposal development 18
During the trial 18
Study oversight 18
Study dissemination 18
Chapter 3 Early stopping 19
Recruitment suspension 19
Informing the Research Ethics Committee 20
Withdrawal of participants from diaphragm pacing system 20
Formal stopping of recruitment 21
Informing Research Ethics Committee, participants and investigators 21
Chapter 4 Trial results 23
Recruitment and participant flow 23
Baseline data 24
Primary outcome (overall survival) 25
Primary overall survival analyses 25
Overall survival at Data Monitoring and Ethics Committee intervention 26
Subgroup analyses of overall survival (preplanned) 26
Non-invasive ventilation and pacing usage 32
Non-invasive ventilation use 32
Pacing use 33
Overall survival by non-invasive ventilation and pacing 36
Non-invasive ventilation use and overall survival 36
Pacing use and overall survival 39
Non-invasive ventilation, pacing and overall survival 39
Secondary outcomes 41
Tracheostomy and tracheostomy-free survival 41
Participant quality of life 41
Carer quality of life 44
Relationship between quality of life, pacing and baseline symptoms 46
Resource use 47
Safety 48
Adverse events 48
Serious adverse events 49
Adverse events related to surgery or pacing 50
Cause of death 50
Physiological measurements 52
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
Chapter 5 Qualitative substudy 65
Outcomes 65
Qualitative substudy methods 65
Sampling 65
Data collection 65
Data analysis methods 66
Participant characteristics 66
Usage of the diaphragm pacing system 66
Results 66
Patient and carer experiences 66
The surgery 67
Operating the equipment 68
Impact on life 70
Perceived outcomes 73
Chapter 6 Discussion 75
Main findings 75
Survival in relation to non-invasive ventilation and diaphragm pacing use and compliance 76
Qualitative study 76
Understanding the results 77
The results of the Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis trial
in context 78
The Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis trial population
compared with other studies of diaphragm pacing 78
Delivery of diaphragm pacing in the Diaphragm Pacing in patients with Amyotrophic
Lateral Sclerosis trial compared with other studies 79
Other confounders 79
Limitations 79
Developments since the completion of the Diaphragm Pacing in patients with
Amyotrophic Lateral Sclerosis trial 80
Chapter 7 Conclusions 81
Meaning of the study and implications for clinicians or policy-makers 81
Recommendations for future research 81
Acknowledgements 83
References 87
Appendix 1 Changes to protocol 91
Appendix 2 Trial summary 95
Appendix 3 Participant flow in each trial arm 97
Appendix 4 Screening and randomisation 99
Appendix 5 Patient information sheet: patient 101
Appendix 6 Patient information sheet: carer 107
Appendix 7 Patient information sheet: patient qualitative 111
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
Appendix 8 Patient information sheet: carer qualitative 115
Appendix 9 Consent form: patient 119
Appendix 10 Consent form: carer 121
Appendix 11 Consent form: patient qualitative 123
Appendix 12 Consent form: carer qualitative 125
Appendix 13 Statistical analysis plan 127
Appendix 14 Stop pacing patient letter (diaphragm pacing arm) 171
Appendix 15 Stop pacing patient letter (non-invasive ventilation arm) 175
Appendix 16 Stop pacing general practitioner cover letter (diaphragm pacing
arm) 177
Appendix 17 Pacing discontinuation standard operating procedure 179
Appendix 18 Qualitative interview topic guide 183
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
List of tables
TABLE 1 Overview of components of DPS 8
TABLE 2 Baseline data 24
TABLE 3 Sensitivity analyses 27
TABLE 4 Statistical significance of the overall survival difference during
data collection 27
TABLE 5 Average daily NIV usage after initiation 33
TABLE 6 NIV settings at initiation and at final visit 34
TABLE 7 NeuRX RA/4 DPS settings 35
TABLE 8 Pacing usage 36
TABLE 9 Overall survival by bulbar function and by NIV use 38
TABLE 10 Quality of life 42
TABLE 11 Resource use 47
TABLE 12 Adverse events 48
TABLE 13 Serious adverse events 49
TABLE 14 Adverse events related to pacing 51
TABLE 15 Cause of death 52
TABLE 16 Changes to protocol 91
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii

List of figures
FIGURE 1 Participant flow diagram 6
FIGURE 2 Trial profile (CONSORT diagram) 23
FIGURE 3 Overall survival 26
FIGURE 4 Survival at 10 December 2013 28
FIGURE 5 Survival at 10 June 2014 28
FIGURE 6 Overall survival by bulbar function 29
FIGURE 7 Overall survival by NIV use 31
FIGURE 8 Average daily NIV usage after initiation 33
FIGURE 9 Survival by NIV use: NIV use in hours 37
FIGURE 10 Survival by NIV use: NIV use category 38
FIGURE 11 Survival by pacing use 39
FIGURE 12 Relationship between NIV and pacing use 40
FIGURE 13 Overall survival by pacing and NIV use 40
FIGURE 14 The EQ-5D-3L health utility among surviving participants over time:
EQ-5D-3L health tariff 41
FIGURE 15 The EQ-5D-3L health utility among surviving participants over time:
patient EQ-5D-3L health tariff, deaths imputed as zero 42
FIGURE 16 The SF-36 aggregate physical health component 44
FIGURE 17 The SF-36 aggregate mental health component 44
FIGURE 18 Sleep Apnoea Quality of Life Index 45
FIGURE 19 Carer EQ-5D-3L health tariff 45
FIGURE 20 Caregiver Burden Inventory 45
FIGURE 21 Change (12 months – baseline) in SAQLI score in relation to baseline
SAQLI score (Q12–Q14) 46
FIGURE 22 Change (12 months – baseline) in SAQLI score in relation to baseline
ALSRFS-r sum (Q11–Q12) 46
FIGURE 23 Forced vital capacity against time for implanted participants 53
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
FIGURE 24 Forced vital capacity against time for non-implanted participants 55
FIGURE 25 The PaCO2 against time for implanted participants 57
FIGURE 26 The PaCO2 against time for non-implanted participants 58
FIGURE 27 The ALSRFS-R score against time for implanted participants 60
FIGURE 28 The ALSRFS-R score against time for non-implanted participants 62
FIGURE 29 The patient journey trialling DP 67
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
List of boxes
BOX 1 Adverse events related to surgery or pacing 50
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii

List of abbreviations
AE adverse event
ALS amyotrophic lateral sclerosis
ALSFRS-R Amyotrophic Lateral Sclerosis
Functional Rating Scale – Revised
CBI Caregiver Burden Inventory
CI confidence interval
CONSORT Consolidated Standards of
Reporting Trials
CTRU Clinical Trials Research Unit
DiPALS Diaphragm Pacing in patients with
Amyotrophic Lateral Sclerosis trial
DMEC Data Monitoring and Ethics
Committee
DP diaphragm pacing
DPS diaphragm pacing system
EPG external pulse generator
EQ-5D-3L European Quality of Life-5
Dimensions, three levels
FDA Food and Drug Administration
FVC forced vital capacity
GP general practitioner
HDE humanitarian device exemption
HR hazard ratio
HUD humanitarian-use device
IQR interquartile range
NIV non-invasive ventilation
PaCO2 partial pressure of carbon dioxide
PI principal investigator
PPI patient and public involvement
QoL quality of life
RCT randomised controlled trial
REC Research Ethics Committee
SAE serious adverse event
SAQLI Sleep Apnoea Quality of Life Index
questionnaire
SF-36 Short Form questionnaire-36 items
SMNDRAG Sheffield Motor Neurone Disease
Research Advisory Group
SNIP Sniff Nasal Inspiratory Pressure
SOP standard operating procedure
SSPB summary of safety and probable
benefit document
TFS tracheostomy-free survival
TMG Trial Management Group
TSC Trial Steering Committee
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix

Plain English summary
The research study aimed to compare two different treatments [non-invasive ventilation alone ornon-invasive ventilation given alongside diaphragm pacing (DP)] for patients experiencing breathing
difficulties due to amyotrophic lateral sclerosis (ALS). ALS is another name for motor neurone disease.
Non-invasive ventilation is the treatment patients usually get where they wear a face mask and air is
pushed into the lungs to help breathing. DP is a possible alternative treatment in which wires are inserted
into the main breathing muscle to stimulate it directly to help patients breathe. The main outcomes of the
study were to see if the addition of DP improved patient survival (how long patients lived) and improved
quality of life.
We conducted our research in seven UK hospitals and enrolled 74 patients to the study (37 patients in
each treatment group). Patients were enrolled between December 2011 and December 2013. The study
stopped early based on recommendations from the committee charged with guarding patient safety.
The committee felt that DP might be causing harm to patients. Patients in the group given DP alongside
standard treatment had worse average survival (11.0 months) than those in the standard treatment only
(non-invasive ventilation) group (22.5 months).
Based on study results, DP should not be used as routine treatment in ALS patients with breathing problems.
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Scientific summary
Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in death, usually from
respiratory failure, within 2–3 years of symptom onset. Affected individuals experience increasing weakness
affecting the limbs, speech and swallowing, and breathing. Management is largely aimed at easing
symptoms and supporting patients to maximise their function through a multidisciplinary approach.
One treatment, riluzole, can marginally slow down disease progression, prolonging survival, usually by
around 3 months.
Non-invasive ventilation (NIV) is a treatment that, when given to patients in respiratory failure, leads to
improved survival and quality of life (QoL). A randomised controlled trial (RCT) demonstrated an
improvement in QoL and a median survival benefit of approximately 7 months (p= 0.006) in ALS patients
using NIV who had good bulbar function. However, some individuals are unable to tolerate using the mask
and there comes a point in the course of the disease when NIV is no longer effective.
The NeuRX® RA/4 diaphragm pacing system (DPS)™ (Synapse Biomedical, Oberlin, OH, USA) is a
four-channel percutaneous neuromuscular stimulation system that may offer additional or alternative
benefits to patients with ALS in respiratory failure. Stimulating electrodes are inserted into the
undersurface of the diaphragm, using a minimally invasive laparoscopic technique. The leads (including an
additional anode) are then tunnelled to an exit site on the abdomen and an external stimulator delivers the
stimulus pulses.
Initial experience with the NeuRX RA/4 DPS in the spinal cord injury population suggested diaphragm
pacing (DP) could reduce time spent on mechanical ventilation. The NeuRX RA/4 DPS is now licensed for
use in spinal cord injury across many countries, including the USA, and within the European Union.
To date, the evidence base for DPS in the ALS population is limited to a case series and one uncontrolled,
multicentre cohort study for which the full data have not been published. Their findings are consistent
with those from the spinal cord patient population, and highlighted the apparent simplicity and operative
safety of the NeuRX RA/4 DPS. The US Food and Drug Administration approved the NeuRX RA/4 DPS as a
humanitarian-use device in ALS following the submission of a humanitarian device exemption application.
Following the humanitarian-use device approval of the NeuRX RA/4 DPS for ALS there has been increasing
use of this therapeutic option worldwide. The promising survival data, lack of apparent harm and absence
of alternatives have made this an appealing option, especially among patients who are unable to tolerate
NIV, who may account for up to 50% of patients with ALS. Moreover, pacing is expensive and it is not
known if DPS would meet the National Institute for Health and Care Excellence threshold for cost-effective
interventions for end-of-life care. Therefore, although the preliminary data are promising, DPS is unlikely to
be widely introduced without robust, randomised evidence together with formal analysis of cost-effectiveness.
This was our motivation for undertaking the Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis
(DiPALS) trial.
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Objectives
The aim of this study was to perform a definitive RCT of the efficacy and long-term safety of the NeuRX
RA/4 DPS when used in addition to NIV, compared with standard care of NIV alone in patients with ALS.
We planned to test the following specific hypothesis:
l The use of DPS in addition to NIV will improve overall patient survival.
We also planned to evaluate the effect of DP in addition to NIV on:
l QoL of participants
l QoL of the main carer
l safety [adverse events (AEs)] and tolerability (withdrawal from treatment)
l quality-adjusted life-years
l views and perceptions of patients and family carers regarding acceptability and impact on life.
Methods
The DiPALS trial was a multicentre, parallel-group, open-label RCT incorporating health economic analyses
and a qualitative longitudinal substudy. Patients aged 18 years or above with a confirmed diagnosis of
ALS (familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according
to the World Federation of Neurology El Escorial criteria) were identified from seven participating UK
hospitals. Patients were confirmed as eligible for the trial if they had been stabilised on riluzole therapy and
had respiratory insufficiency and clinically acceptable bilateral phrenic nerve function.
Respiratory insufficiency was determined by one or more of:
1. forced vital capacity (FVC) < 75% predicted
2. supine vital capacity < 75% of sitting or standing vital capacity
3. sniff nasal inspiratory pressure (SNIP) < 65 cmH2O for men or 55 cmH2O for women in the presence
of symptoms
4. SNIP < 40 cmH2O in the absence of symptoms
5. partial pressure of carbon dioxide (PaCO2) > 6 kPa (daytime) or PaCO2 > 6.5 kPa (overnight)
6. significant overnight O2 desaturation (> 5% of night with peripheral capillary oxygen saturation < 90%).
Phrenic nerve function defined as clinically acceptable by:
1. absence of paradoxical abdominal wall movement during a sniff manoeuvre (sharp inhalation through
the nose) and recording < 10% decline of FVC when moving from sitting to supine position, or
2. on ultrasound: evidence of at least 1 cm of downward diaphragm movement independent of thoracic
or abdominal wall movement during the patient performing a sniff manoeuvre.
Patients were not recruited to the trial if they met any of the exclusion criteria:
1. prior NIV prescription
2. pre-existing implanted electrical device such as pacemaker or cardiac defibrillator
3. underlying cardiac or pulmonary diseases, or other disorders that would affect pulmonary tests
independently of ALS (increased risk of general anaesthesia or adverse effect on survival over the course
of the study)
4. women who were pregnant or breastfeeding at the time of screening
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5. significant decision-making incapacity (patient suffered from major depression, schizophrenia, dementia
or similar disorder) preventing informed consent by the patient
6. marked obesity affecting surgical access to diaphragm or significant scoliosis/chest wall deformity
7. the involvement in any respiratory trial that could have influenced the safety or outcome measures of
the study within 3 months of the planned implantation of the device or during the year of follow-up
8. pre-existing diaphragm abnormality such as a hiatus hernia or paraoesophageal hernia of abdominal
contents ascending into the thoracic cavity
9. FVC < 50% predicted or SNIP < 30 cmH2O in patients unable to perform FVC (bulbar patients)
(because of potential anaesthetic risk).
Recruited patients were randomly allocated to treatment group using a centralised randomisation system.
Patients were allocated their treatment (NIV alone or NIV plus DPS) by method of minimisation, using
baseline bulbar function, baseline FVC, age and sex as the minimisation factors.
The primary outcome was overall survival. Secondary outcomes were quality-adjusted life-years
[European Quality of Life-5 Dimensions, three levels (EQ-5D-3L)], QoL of the patient (EQ-5D-3L, Short Form
questionnaire-36 items and Sleep Apnoea Quality of Life Index questionnaire); QoL of the main carer
(EQ-5D-3L and Caregiver Burden Inventory); safety and tolerability of the device; health economic
objectives and resource use; and perceptions of patients and carers regarding acceptability and impact of
the device.
Follow-up visits were conducted at clinic (1 week, and at 2 months, 3 months, 6 months, 9 months and
12 months). Trial data were collected on the study case report form and patient diary and were entered
into a validated bespoke web-based database system (Prospect) managed by the Sheffield Clinical Trials
Research Unit (CTRU). Sheffield CTRU has developed Prospect in collaboration with epiGenesys (a software
development company wholly owned by the University of Sheffield). Prospect’s validation status reflects
our approach of continuous development, so is not identified by a formal version number or release date.
The source code version control system records all changes and associates these with a specific revision
number. Prospect is hosted on servers operated by the University of Sheffield Corporate Information and
Computing Services (CiCS) department.
We planned to recruit 108 patients (54 per group) to ensure a power of 85% using a two-sided type I
error of 5%. The sample size was estimated based on log-rank test, using Simpson’s rule, and estimated
on a conservative (but clinically important) 1-year difference in survival of 45% versus 70%, which
produced the estimated hazard ratio (HR) of 0.45.
Statistical analyses were by intention to treat, with preplanned secondary analyses of overall survival based
on protocol adherence and NIV use. A significance level of 5% was used for significance testing, and all
confidence intervals (CIs) were two-sided 95% intervals.
The primary end point was overall survival, defined as the time from randomisation to death from any
cause. Overall survival was compared between the groups using the log-rank test and modelled using
Cox proportional hazards regression, with the minimisation factors as covariates. QoL was analysed both
longitudinally (i.e. over the duration of the trial rather than individual time points) and at the end of the
study follow-up (12 months).
Average NIV use was defined as the average number of hours used from the date of NIV initiation
onwards, and DPS usage was defined as the average daily use from the date of procedure onwards.
The relationship between NIV and DPS usage by time point was also assessed. NIV use by participants was
categorised as non-adherence (typical usage below 1 hour per day), low adherence (typical usage 1 to
< 4 hours per day) or good adherence (typically ≥ 4 hours per day).
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Adverse events and serious AEs were coded by the chief investigator blind to the participant’s treatment group.
AEs were summarised for each AE category and overall as the number and percentage of patients affected
and the number of events in total (as the same AE may occur more than once in the same patient).
Sheffield Teaching Hospitals NHS Foundation Trust sponsored the trial (reference STH15625). Oversight
committees were established to govern study conduct: a Trial Management Group, a Trial Steering
Committee and a Data Monitoring and Ethics Committee (DMEC). The trial was conducted in accordance
with CTRU standard operating procedures with committees convening at appropriate intervals as dictated
by both study requirements and standard operating procedures.
Qualitative substudy
A qualitative longitudinal study formed a subelement of the trial design.
The aim of the qualitative component was to evaluate the acceptability and perceived impact of the
intervention on patients with ALS and their family.
Methods
We purposively selected participants for the qualitative element of the study from those randomised to the
pacing intervention arm of the trial. We intended that our sample would include diversity in terms of
patient sex, age and ALS type and across the different ALS centres taking part in the trial.
Qualitative interviews with patients and carers were carried out at two time points: 1 month following
initiation of the pacing intervention and, when possible, 6 months later.
Early stopping
The DMEC recommended early stopping of the trial on safety grounds following review of unblinded
survival data. The DMEC advised initial suspension of recruitment (December 2013), and subsequent
discontinuation of pacing in all patients (June 2014).
Results (research findings)
In total, 74 participants (37 per arm) were randomised between 5 December 2011 and 18 December 2013,
when the DMEC recommended that recruitment cease. Study follow-up concluded in December 2014,
by which time 47 patients had died; one patient was last followed up in August 2014, with the remaining
26 known to be alive in December 2014.
The median survival (interquartile range) was 22.5 months (lower quartile, 11.8 months’ upper quartile not
reached) months in the NIV arm and 11.0 months (6.7–17.0 months) in the NIV plus pacing arm, with an
adjusted HR of 2.27 (95% CI 1.22 to 4.25; p= 0.01). Patient QoL during 12-month follow-up was lower in
the NIV plus pacing arm when assessed by EQ-5D-3L, but was similar on other measures. Carer QoL was
similar on all measures.
Non-invasive ventilation was initiated in 70 out of 74 patients. Overall, 57 patients were initiated within
2 weeks of randomisation, a further six within 1 month and the remaining seven between 3 and
11 months. NIV use was similar in the two groups; the median (interquartile range) in the NIV plus pacing
arm was 3.2 hours (0.5–8.2 hours) and in the NIV arm was 4.6 hours (0.0–7.8 hours).
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Five pacing group participants did not undergo surgery; the reasons were respiratory function below safety
threshold (n= 1), patient choice (n= 2) and DMEC intervention (n= 2). A sixth patient stopped pacing
within 1 month because of device technical issues.
Implantation was successful for all who underwent surgery. When used, the median daily usage was
4.6 hours (interquartile range 3.0–8.4 hours), with target pacing largely achieved by 15 days.
Fourteen patients took part in the qualitative substudy; nine were interviewed both immediately following
initiation of DP and 6 months later. The device was described as being easy to operate, having little
impact on life, and was often preferred to NIV. Tolerance of DP varied, with some patients experiencing
significant levels of pain, whereas others reported only a noticeable but minor sensation. Patients described
hope that the intervention would lead to benefits in the longer term; however, few perceived any
direct gains.
Conclusions
Meaning of the study and implications for clinicians or policy-makers
Diaphragmatic pacing should not be used as a routine treatment for patients with ALS in respiratory
failure. We cannot exclude that in subgroup of patients there is a benefit; however, this should not be
assumed. Our findings demonstrate that insertion of the NeuRX RA/4 DPS is harmful when instigated
at the point at which an individual with ALS develops respiratory failure. A study investigating whether
or not implanting earlier in the ALS disease trajectory is of benefit has recently been suspended, and the
full results from this study are awaited (NCT01583088). DPS has also been approved for use in the spinal
cord injury population. Before widespread use of DPS in the spinal cord injury population, or indeed other
populations, we suggest that the evidence base needs to be firmly established.
A poor prognosis and the absence of curative therapy understandably encourage a ‘nothing to lose’
approach among patients and some clinicians alike, with an attendant lowering of the standards of
evidence required to adopt a new intervention. Our trial demonstrates the potential for harm that can arise
from adopting this approach. We strongly recommend that all interventions be subjected to appropriate
study, which will usually mean a RCT, before adoption into routine practice. This should apply to medical
devices, particularly those that expected to have an impact on survival or necessitate invasive procedures.
Recommendations for future research
We cannot exclude that a subgroup of highly selected individuals might benefit from DP, for example
those with predominantly upper motor neurone disease. Future work may focus on exploring such
uncertainties. Any further studies should include measures to understand the mechanism by which harm
or benefit occurs as a result of DP.
Trial registration
This trial is registered as ISRCTN53817913.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. Additional funding was provided by the Motor Neurone Disease Association
of England, Wales and Northern Ireland.
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Chapter 1 Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an annual incidence of 2–3 in100,000 and a prevalence of 5–8 per 100,000.1–3 Affected individuals experience increasing weakness
affecting the limbs, speech and swallowing, and breathing. There is no cure for ALS and patients usually
succumb to the illness within 2–3 years.
Management of amyotrophic lateral sclerosis
Management is largely aimed at easing symptoms and supporting patients to maximise their function
through a multidisciplinary approach.4 One treatment, riluzole, can marginally slow down disease
progression, prolonging survival, usually by around 3 months.5,6 The exact mechanism by which riluzole
affects the disease course is unclear, although it is known to modulate glutamate release, among other
effects. However, the greatest impact on the disease course comes from the use of non-invasive ventilation
(NIV). A randomised controlled trial (RCT) demonstrated an improvement in quality of life (QoL) and a
median survival benefit of approximately 7 months (p= 0.006), in ALS patients using NIV who had good
bulbar function.7 NIV, however, is not without its problems, as some individuals are unable to tolerate it
because of problems with claustrophobia and mask interface issues. Furthermore, there comes a point in
the course of the disease when NIV is no longer effective.
Phrenic nerve stimulation, in which the diaphragm is stimulated into contracting, is a potential alternative
or complementary method of providing respiratory support. The approach originated in patients with
spinal cord injury, and historically it required direct phrenic nerve stimulation. The challenges with this
approach have been the significant risk of iatrogenic phrenic nerve injury and, until recently, the need to
undertake a thoracotomy.8 More recently, phrenic nerve stimulation has been achieved using less invasive
techniques. The NeuRX® RA/4 diaphragm pacing system (DPS)™ (Synapse Biomedical, Oberlin, OH, USA) is
a four-channel percutaneous neuromuscular stimulation system. DPS has an advantage over the earlier
direct approach, in that the stimulating electrodes can be inserted into the under-surface of the diaphragm
using a minimally invasive laparoscopic technique.9 The leads are then tunnelled to an exit site on the
abdomen and an external stimulator delivers the stimulus pulses and provides respiratory timing. Initial
experience with the NeuRX RA/4 DPS in the spinal cord injury population10 suggested diaphragm pacing
(DP) could reduce time spent on mechanical ventilation.11 The NeuRX RA/4 DPS is now licensed for use in
spinal cord injury in many countries, including the USA, and within the European Union.
Evidence for diaphragm pacing in amyotrophic lateral sclerosis
To date, the evidence for DPS in the ALS population is limited to case series and one uncontrolled
multicentre cohort study. Their findings are consistent with those from the spinal cord patient population,
and highlighted the apparent simplicity and operative safety of the NeuRX RA/4 DPS.7,10 The US Food and
Drug Administration (FDA) approved the NeuRX RA/4 DPS as a humanitarian-use device (HUD) in ALS
following the submission of a humanitarian device exemption (HDE) application. The FDA summary of
safety and probable benefit document (SSPB) summarises the evidence on which the HDE approval is
based, which is largely on data from the aforementioned cohort study.11 The main inclusion criteria for the
study were patients with ALS with evidence of residual bilateral phrenic nerve function and a forced vital
capacity (FVC) of less than 85% at screening and above 45% at DPS implantation. The full data from this
study, including baseline characteristics, Consolidated Standards of Reporting Trials (CONSORT) diagram,
survival, etc., on the 144 patients enrolled have not yet been published. Of the 144, 106 were implanted
with the NeuRX RA/4 DPS and survival data on 84 are presented in the SSPB.11
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Median survival data are reported as 39 months from ALS diagnosis and 19 months post implantation in
the SSPB on 84 implanted patients. As the data are from a cohort study there is no randomised control
population to compare survival with. Instead, a subgroup of the HUD patients (n= 43) was compared with
a historical control group of NIV users. The DP HUD group patients demonstrated survival of 37.5 months
from diagnosis, compared with 21.4 months from diagnosis for the historical NIV control group (p< 0.001).
Safety data have been published in the SSPB for 86 implanted patients from the cohort study. In these
patients, there were no reported deaths and none who needed a tracheostomy with permanent ventilation
within the 30-day postoperative period. Four serious adverse events (SAEs) were reported relating to
implantation [capnothorax (n= 2), respiratory failure due to complications of surgery (n= 1) and serious
anaesthetic reaction (n= 1)]. Therefore, the implantation procedure itself appeared to be relatively safe.
Important adverse events (AEs) over the 12-month protocol reported were capnothoraces in 16 patients
(19%), percutaneous site infection in eight patients (9%) and pacing-related discomfort, which was
described as mild in 20 patients (23%) and moderate in two patients (2%). In the 86 patients implanted,
there were no SAEs involving malfunctioning device components. There were 18 reports of anode
malfunction in 18 patients (21%) and 44 reports of electrode malfunction in 28 patients (33%). Although
there was relatively frequent electrode breakage, there was no need to reimplant any electrodes, as all
occurred external to the body at the connector holder.
Following the HUD approval of the NeuRX RA/4 DPS for ALS, there has been increasing use of this
therapeutic option worldwide.12 The promising survival data, lack of apparent harm and absence of
alternatives have made this an appealing option, especially among patients who are unable to tolerate NIV,
who may account for up to 50% of patients with ALS.2,3,13,14 The evidence base for the NeuRX RA/4 DPS
for ALS is limited. Moreover, pacing is expensive and it is not known whether or not DPS would meet the
National Institute for Health and Care Excellence’s threshold for cost-effective interventions for end-of-life
care. At the time of conducting the Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis
(DiPALS) trial, the cost of DPS and implantation procedures (the excess treatment costs) was approximately
£16,500 per participant. Therefore, although the preliminary data are promising, DPS is unlikely to
be widely introduced without robust, randomised evidence together with a formal analysis of
cost-effectiveness. This was our motivation for undertaking the DiPALS trial.
Research objectives
The aim of this study was to perform a definitive RCT on the efficacy and safety of the NeuRX RA/4 DPS
when used in addition to NIV, compared with standard care of NIV alone, in patients with ALS. Specifically,
we wished to assess whether or not the use of DP in addition to NIV prolongs survival, and also to quantify
its impact on:
l QoL of the participant
l QoL of the main carer
l safety (AEs) and tolerability (withdrawal from treatment)
l quality-adjusted life-years
l views and perceptions of patients and family carers regarding acceptability and impact on life.
INTRODUCTION
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Chapter 2 Methods
The original protocol for DiPALS was submitted to BMC Neurology15 and was published 8 months intothe recruitment phase of the trial, prior to any analyses being performed. The methods described in this
chapter are consistent with those as published and with the conduct of the trial in practice, but changes
were made to the protocol over the course of the project. These are detailed at the end of this chapter,
and tabulated in Appendix 1. None of the changes affected the conduct of the trial with respect to the
intervention, the primary outcome measures or their statistical analyses.
This report has been prepared in accordance with the CONSORT statement (2010)16 and the Template for
Intervention Description and Replication checklist and guide.17
Trial design
The DiPALS trial was a multicentre, parallel-group, open-label RCT incorporating health economic analyses
and a qualitative longitudinal substudy. The primary objective was to assess survival over the study duration
of patients with ALS with respiratory failure, allocated to either standard care (NIV alone) or standard care
(NIV) plus DPS using the NeuRX/4 DPS. Participants from seven UK hospitals were allocated to treatment
using minimisation methods (see Appendices 2 and 3).
The trial was non-commercial, with input from Synapse Biomedical for quality assurance purposes,
specifically for the training of surgeons and trial staff on implantation and technical aspects of the
NeuRX/4 DPS.
Recruitment took place over 24 months (from December 2011 to December 2013).
Participants and eligibility criteria
Patients aged ≥ 18 years with a confirmed diagnosis of ALS were identified and screened at participating
sites or patient referral sites against the following eligibility criteria.
Inclusion criteria
1. Aged ≥ 18 years.
2. Familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to
the World Federation of Neurology El Escorial criteria.18
3. Stabilised on riluzole therapy for at least 30 days.
4. Respiratory insufficiency as determined by one or more of:
i. FVC < 75% predicted
ii. supine vital capacity < 75% of sitting or standing vital capacity
iii. sniff nasal inspiratory pressure (SNIP) < 65 cmH2O for men or 55 cmH2O for women in the presence
of symptoms
iv. SNIP < 40 cmH2O (see exclusion criterion 9).
v. partial pressure of carbon dioxide (PaCO2) > 6 kPa (daytime) or PaCO2 > 6.5 kPa (overnight)
vi. significant overnight O2 desaturation (> 5% of night with SpO2 < 90% during overnight oximetry).
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5. Bilateral phrenic nerve function clinically acceptable as defined by either:
i. absence of paradoxical abdominal wall movement during a sniff manoeuvre (sharp inhalation
through the nose) and recording < 10% decline of FVC when moving from sitting to supine
position, or
ii. on ultrasound: evidence of at least 1 cm of downward diaphragm movement independent of
thoracic or abdominal wall movement during the patient performing a sniff manoeuvre.
Exclusion criteria
1. Prior NIV prescription.
2. Pre-existing implanted electrical device such as pacemaker or cardiac defibrillator.
3. Underlying cardiac, pulmonary diseases or other disorders that would affect pulmonary tests
independently of motor neurone disease/ALS (increased risk of general anaesthesia or adverse effect on
survival over the course of the study).
4. Current pregnancy or breastfeeding.
5. Significant decision-making incapacity preventing informed consent by the subject because of a major
mental disorder such as major depression, schizophrenia or dementia.
6. Marked obesity affecting surgical access to diaphragm or significant scoliosis/chest wall deformity.
7. The involvement in any respiratory trial that can influence the safety or outcome measures of this study
within 3 months of the planned implantation of the device or during the year of follow-up.
8. Pre-existing diaphragm abnormality such as a hiatus hernia or paraoesophageal hernia of abdominal
contents ascending into the thoracic cavity.
9. FVC < 50% predicted or SNIP < 30 cmH2O in patients unable to perform FVC (bulbar patients)
(because of potential anaesthetic risk).
Participant identification
Potentially eligible patients were identified from NHS hospital clinics at lead research sites or participant
identification centres by neurology or respiratory clinicians or a study research nurse (see Appendix 4).
All patients aged ≥ 18 years with a confirmed diagnosis of ALS underwent a ‘prescreen’ whereby their last
routine respiratory measure was checked to determine whether or not:
1. patients were ineligible because of poor respiratory criteria or other reason
2. patients were potentially eligible
3. patients may be eligible in the future as their respiratory measure was currently too good.
All those potentially eligible were approached at clinic to discuss the trial in detail. If they were identified
from the clinic list prior to attendance the study information was sent to them by post.
Recruitment
Patients were approached by a member of the research team at sites when they attended routine clinic
appointments. The study patient and carer information sheets formed a basis for a discussion with
potential participants in clinics. Patients were given as long as they required to consider taking part in the
trial, with further discussion by telephone or at another clinic offered. Informed consent was taken only
if the researcher was satisfied that the patient fully understood the study procedures, was willing to
undergo screening and participate in the trial, and was capable of giving full informed consent. Consent
was obtained using participant and carer consent forms approved by the Research Ethics Committee (REC),
as either full written consent, verbal consent given or consent given via the use of a communication aid
METHODS
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(for REC-approved patient information sheets see Appendices 5–8 and for REC-approved consent forms
see Appendices 9–12). When non-written consent was obtained an independent witness was asked to
sign the consent form to verify that consent was taken.
If participants were willing to provide reasons for declining participation in the trial, these were entered
onto the screening log. Anonymised basic details (age, sex and reason for exclusion) were collected on all
eligible patients to allow completion of the CONSORT flow chart.
Participants were free to withdraw from the trial at any point without giving a reason, but data collected
up to the point of study withdrawal were maintained and used in study analyses. Patients who asked
to withdraw from treatment were encouraged to complete follow-up for QoL and safety to reduce attrition
bias. All participants were followed up for survival until 12 months after the last participant was recruited,
unless they specifically requested otherwise (Figure 1).
Screening
Once patient consent had been confirmed, a member of the site study team initiated the screening
process. Patient eligibility was assessed against both non-clinical and clinical criteria, and baseline
assessments. Eligibility for the study was based on all the inclusion and none of the exclusion criteria being
met. To confirm eligibility, a combination of techniques was used. Researchers checked medical notes/data
to assess past medical history, current prescriptions and any other known information relating to eligibility
criteria. At the screening visit, participants were asked to perform a respiratory test to determine their
FVC or other measure. An assessment was made of the participant’s phrenic nerve function – a measure
intended to ensure that, if the patient were randomised to DPS, it was likely that it would be possible to
sufficiently stimulate the participant’s diaphragm once the system was fitted. All criteria were checked and
signed off by the recruiting clinician. Once eligibility was established, participants were asked to complete
baseline assessments and could proceed to randomisation and study procedures (see Figure 1).
Randomisation and blinding
Once eligibility had been confirmed and consent acquired, the participants were randomly allocated to a
treatment group. The recruiting clinician accessed a centralised web-based randomisation system provided
by the Sheffield Clinical Trials Research Unit (CTRU) in partnership with a University of Sheffield wholly
owned subsidiary software development company, epiGenesys. Sites were able to log on to the system
using a site-specific username and password. Researchers were prompted to enter patient details
(identification number, date of birth and the minimisation factors) and to confirm that consent and
eligibility was complete. Following this, the randomisation system notified the user and the study manager
of the treatment allocation. Patients were informed of their treatment allocation within 1 week of
randomisation by telephone or letter.
The study was open label; it was not considered feasible to blind participants, carers or site staff as the
study intervention involves a surgical procedure and ongoing use of an implanted medical device. A sham
surgical procedure was considered but discounted as being an unnecessary burden to participants, given
the objectivity of the primary outcome measure.
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Participant randomised to the trial
NIV arm
Patient attends clinic for NIV
initiation as per usual clinical
practice. Record baseline NIV
settings, NIV prescription given,
type of interface, humidification
and type of machine recorded
Take home patient diary
Follow-up visits:
Patient attends 2-, 3-, 6-, 9-a and 
12-month visits
Data: SF-36, SAQLI, EQ-5D-3L, CBI, 
DPS and NIV use and
settings, resource use, AE/SAEs
DPS arm
Patient attends clinic/hospital for initiation of
NIV as per usual clinical practice. We have
compared baseline scores with 12-month
averages in EQ-5D-3L, SF-36 physical,
SF-36 mental and total SAQLI and see
 no relationship between symptoms present 
and quality of life scores 
Take home patient diary
Patient attended hospital up to 7 days before
planned operation date
If patient failed
pre-operative check:
withdrawn from
treatment
Fail patient
withdrawn from
treatment
Repeat pre-operative check
Pass proceed to surgery
Surgery 
DPS switched on 
within 7 days
Patients usually
discharged 
1 – 2 days 
post surgery.
Take home
patient carer
manual
Patient attends 
1-week safety visit
Patient passed
pre-operative check:
proceed to surgery
Site study team
member reviews patient
for new or recurrent
illness that may affect
safety for surgery
Site study team
member collected final
survival status for all
patients following last
patient last visit
If patient failed
pre-operative check
owing to other
complication: assessed if
could recall for surgery
FIGURE 1 Participant flow diagram. a, At 9 months, only ED-5D-3L, DPS/NIV use, AEs and resource use collected.
CBI, Caregiver Burden Inventory; EQ-5D-3L, European Quality of Life-5 Dimensions, three levels; SAQLI, Sleep
Apnoea Quality of Life Index questionnaire; SF-36, Short Form questionnaire-36 items.
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Patients were allocated their treatment (NIV alone or NIV plus DPS) by method of minimisation, using
baseline bulbar function, baseline FVC, age and sex as the minimisation factors. Factors were
categorised as follows: bulbar function (mild, moderate or severe); FVC (50–59%, 60–69% or ≥ 70%);
age (≤ 39 years, 40–79 years or ≥ 80 years); and sex (male or female). The allocation incorporated a
burn-in period of 10 participants (i.e. the first 10 participants were allocated using simple randomisation).
Thereafter, allocation was performed using minimisation incorporating a random probability element of
80% into the allocation algorithm. That is each participant was allocated to the arm that reduced
treatment imbalance with 80% probability and to the opposite arm with 20% probability.
The minimisation system was prepared by the study statistician; the study team did not have access to the
allocation list in order to maintain allocation concealment. The study team and governance committees
were blinded during the course of the study with the following exceptions: (1) the trial statistician and
data management team had full access to unblinded outcome data; (2) the Data Monitoring and Ethics
Committee (DMEC) had access to unblinded summaries of outcome data; (3) site staff were aware of the
treatment allocation of their own participants; and (4) the chief investigator, study manager and site
monitor were aware of individual participants’ allocations and AEs but did not see unblinded comparative
summaries. The trial unblinded statistician was responsible for providing the DMEC with the accumulating
unblinded data summaries, but did not attend the closed meetings during which the DMEC reached
its decisions.
The original analysis plan was signed off after recruitment start, by which point one participant had died.
The updated analysis plan was written by the unblinded trial statistician and endorsed with minimal
suggestions by the unblinded DMEC; all other reviewers and approvers did so blinded to outcome data.
Interventions
Participants were randomly allocated to receive either standard care (NIV) or standard care in addition to
DPS using the NeuRX/4 DPS.
Non-invasive ventilation
Non-invasive ventilation was initiated as per usual clinical practice at the study site after randomisation.
Diaphragm pacing system
The NeuRX DPS is licensed for use in patients with ALS (Conformité Européenne certificate number
518356). The FDA approved the device under HDE for patients with ALS who had stimulatable diaphragms
and were experiencing chronic hypoventilation but who had not progressed to a FVC of < 45% of their
predicted capacity.
The system is a four-channel intramuscular, motor point stimulation system. Intramuscular diaphragm
electrodes are implanted laparoscopically into the diaphragm, with leads tunnelled to an exit site on
the abdomen. The external part of the electrodes are connected to an external pulse generator (EPG),
which is a small, white, portable box. A clinical station is used to programme each of the parameters
(pulse frequency, pulse duration, inspiration time, pulse amplitude, pulse ramp and respiratory rate) on
the EPG, which controls the stimulation delivered to the diaphragm via the implanted wires electrodes.
The EPG provides repetitive electrical stimulation to the implanted electrodes allowing the diaphragm to
contract in a manner that mimics breathing.
The Motor Neurone Disease Association provided funding for the purchasing of the NeuRX DPSs from the
manufacturers of the device, Synapse Biomedical, which supplied them at reduced cost. The DPS system
consists of components to both allow implantation of the electrodes into the diaphragm and its
subsequent stimulation (Table 1).
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Members of the surgical team were responsible for clinical implantation of the system (see Surgical
implantation). Theatre staff processed the electrode delivery instrument to allow its use in theatre including
sterilisation and maintenance. Local procedures at each hospital for implanting the device were followed
in order to complete documentation to allow sites to receive the system. Hospital medical equipment
departments checked equipment prior to use following local hospital procedures.
Surgical implantation
On randomisation, the research nurse made arrangements for the participant to have DPS fitted. The time
elapsed between randomisation and surgery varied according to availability, but the protocol encouraged
investigators to fit the DPS within 8 weeks of randomisation. Participants were booked for a preoperative
assessment up to 1 week prior to the operation to ensure their respiratory criteria remained within the safe
range (FVC ≥ 45% and SNIP ≥ 30 cmH2O) and to check they were otherwise able to undergo the procedure
safely. The research nurse liaised with the trial manager, surgeons and anaesthetists and members of
Synapse Biomedical to organise a theatre slot and medical equipment for the procedure. A member of
Synapse Biomedical was present at each operation to provide verbal assistance to the surgeon including
mapping the diaphragm and implantation of electrodes at the point of maximal stimulation, as per current
standard practice. Synapse Biomedical technical staff received honorary contracts to attend each surgical
procedure. Guidance was also provided by Synapse Biomedical in setting the DPS parameters postoperatively.
The clinicians performing the procedure in the treatment arm were experienced surgeons who received
training in the DPS implantation technique and were competent to perform the procedure. The training
process was straightforward as the technique is a modification of a standard abdominal laparoscopic
procedure, and mirrored that employed in the previous DP cohort study.11 Training was provided by
a surgeon from Synapse Biomedical. Given the simplicity of the implantation of electrodes for an
experienced laparoscopic surgeon, all surgeons were judged competent by Synapse Biomedical after
observation of one implantation procedure. Again this reflects the training of surgeons in the previous
multicentre cohort study. A single surgeon undertook procedures in six of the centres; the seventh
(London) referred participants in the intervention arm to undergo surgery at the Oxford site. At all
surgeries, Synapse Biomedical technical staff were present to advise on implantation.
During the implantation procedure, incisions of 0.5–1 inch long were made in the abdomen. More than
one incision was made to enable instruments to be passed through the abdominal wall as per standard
laparoscopic procedure.
TABLE 1 Overview of components of DPS
Item Description
Clinical station Clinical station used to map the diaphragm during surgery (by surgeon) to find the point of
maximal contraction. Enables programming of the EPG unit to adjust wire parameters at
subsequent visits (by PI/research nurse)
Electrode delivery
instrument
To enable surgical implantation of the device. Used during the laparoscopic procedure by surgeon
Clinical implantation
kit
Electrodes and instruments required for implantation. Used in theatre by the surgeon
Patient kit Includes EPG control unit and cables required for each patient. Used by PI/research nurse at sites
PI, principal investigator.
METHODS
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The surgeon identified the best location to place the electrodes within the diaphragm. A probe was used
to temporarily place an electrode on the surface of the diaphragm and to stimulate the diaphragm muscle
at several locations. Once the best locations were identified, the probe was removed and two electrodes
were placed in each side of the diaphragm muscle. The lead wires from these electrodes travelled under
the skin to the abdominal wall. The wires were trimmed so that the ends sticking out of the skin were only
2–6 inches in length. A radiograph was taken following the surgery to check the position of the wires and
to make sure that no air had travelled above the diaphragm and into the chest. At the end of surgery the
clinical station read out was printed for surgical quality control, which displayed the functioning stimulus
connection for each electrode wire.
An assessment of phrenic nerve function formed part of the screening procedures, as described in this
section. The purpose of this was to assess whether or not there was enough residual phrenic nerve function
to enable meaningful stimulation of the diaphragm with the NeuRX DPS. However, it is only at the time
of the operation when it is possible to know for certain if the diaphragm is stimulatable. If during the
implantation procedure the diaphragm was not stimulatable (no contraction observed during mapping),
then the operation was stopped and the device was not inserted.
Evaluation of electrodes and diaphragm pacing system training
Evaluation of the electrodes and DPS was performed prior to discharge from hospital. A system check of
the wires was completed. Using the clinical station electrode evaluation was performed, by adjusting
individual stimulus parameters (pulse amplitude, width and frequency) to achieve a comfortable level of
stimulation for the diaphragm conditioning sessions. During the initial stimulation period, the participant’s
vital signs were monitored for any abnormalities. The patient was given a daily target for the number
and length of DP sessions, which was recorded by the study team member in the patient diary for the
patient to refer to at home.
Training of the participant and their caregiver took place prior to discharge. This included instruction in the
care and use of the stimulator and data collection in the patient diary. Verbal and written instruction was
provided in a patient/caregiver instruction manual.
Prior to discharge, the participant/or carer was required to show proficiency to the treating clinician in
the following:
l cleaning and care of skin, wires and exit site
l care and use of the stimulator
l attachment and detachment of all components
l completion of patient diary.
It was accepted that initiation of pacing could be deferred until the 1-week postoperative appointment
to allow patients to adjust to having the device fitted in the immediate postoperative period. This was
to match practice at all sites, as it was recognised that this enables the patient to recover after their
operation. Patients were able to turn the EPG control unit ‘on’ or ‘off’ after programming to provide an
adequate stimulus. The initial target for pacing sessions for ALS patients was five times per day, with each
session lasting at least 30 minutes. Patients were asked to build up to this target over the first month.
In the second month, patients were required to gradually lengthen the training sessions. When pacing was
being performed for 6–7 hours a day, patients were instructed to switch from pacing during the day
to using the pacing device overnight while asleep. At this stage patients could additionally use the pacing
device during the day if they felt it benefited them, but this was their decision. Patients were asked to
continue to use their NIV as advised by their study doctor.
A patient diary was given to the participant (on NIV initiation) to take home to record the amount of time
spent on DPS and/or NIV.
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Outcomes
Primary outcome
The primary outcome was overall survival.
Secondary outcomes
l Quality-adjusted life-years, calculated from the European Quality of Life-5 Dimensions, three levels
(EQ-5D-3L) health utility questionnaire.
l QoL, measured by the EQ-5D-3L, Short Form questionnaire-36 items (SF-36) and Sleep Apnoea Quality
of Life Index questionnaire (SAQLI).
l QoL of the main carer, measured by the EQ-5D-3L and Caregiver Burden Inventory (CBI).
l Safety and tolerability of the device.
l Health economic objectives and resource use.
l Perceptions of patients and carers regarding acceptability and impact of the device.
Initially, all of these outcome measures were assessed as per the original protocol; however, as a
consequence of the trial’s early termination (see Chapter 3, Recruitment suspension), the above was
amended. First, both the funder and sponsor agreed that given the substantial cost of the device and the
apparent reduction in life-years in the pacing arm, the planned health economic analyses were now
unnecessary. Second, the Trial Steering Committee (TSC) requested widening the scope of the statistical
analyses to address usage of both NIV and DPS in relation to survival.
We also reported tracheostomy-free survival (TFS), defined as the time from randomisation to either death
or the placement of tracheostomy, whichever occurred first. Although not preplanned, this outcome was
added to aid comparability with other studies that have reported TFS.
Follow-up visits
Follow-up visits were conducted at clinic (at 1 week and at 2, 3, 6, 9 and 12 months). Some questionnaires
were completed via post/e-mail when participants were unable to come into clinic.
Data collection and management
Data collection forms
Data for all participants were captured on the following key sources:
l screening log – prescreening details containing reasons for ineligibility or non-participation
l participant and carer consent forms – informed consent
l case report form – all other study forms including eligibility, baseline assessments, randomisation,
surgery, follow-ups (at 1 week and at 2, 3, 6, 9 and 12 months) study completion (withdrawal),
AEs/SAEs, concomitant medications and, unscheduled DPS visits
l patient diary – DPS and/or NIV usage.
Database
Trial data were entered into a validated bespoke web-based database system (Prospect) managed by the
Sheffield CTRU in partnership with a University of Sheffield wholly owned subsidiary software development
company, epiGenesys. Prospect stores all data in a PostgreSQL 9.1 (open-source software from The
PostgreSQL Global Development Group) database on virtual servers hosted by Corporate Information and
Computing Services at the University of Sheffield. Prospect uses industry standard techniques to provide
security, including password authentication and encryption using Secure Sockets Layer/Transport Layer
METHODS
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Security. Access to Prospect was controlled by usernames and encrypted passwords, and a comprehensive
privilege management feature was used to ensure that users had access to only the minimum number of
data required to complete their tasks. An automated audit trail recorded when (and by which user) records
were created, updated or deleted. Prospect provides validation and verification features which were used
to monitor study data quality, in line with CTRU’s standard operating procedures (SOPs).
Methods used for treatment allocation, sequence concealment
and blinding
Patients were allocated their treatment (NIV alone or NIV plus DPS) by a method of minimisation, using
baseline bulbar function, baseline FVC, age and sex as the minimisation factors. Factors were categorised as
follows: bulbar function (mild, moderate or severe); FVC (50–59%, 60–69% or ≥ 70%); age (≤ 39 years,
40–79 years or ≥ 80 years); and sex (male or female). The minimisation was non-deterministic and
incorporated a burn-in period of 10 participants and a random probability element of 80% into the
allocation algorithm. In other words, the first 10 participants were allocated using simple randomisation;
thereafter, each participant was allocated to the arm that reduced treatment imbalance with 80%
probability and to the opposite with 20% probability. A centralised, web-based randomisation system
hosted by the CTRU was used to allocate treatment allocations. Sites were able to log on to the system
using a site-specific username and password. Researchers were prompted to enter patient details
(identification number, date of birth and the minimisation factors) and to confirm consent and eligibility
were complete. Following this, the randomisation system notified the user and the study manager of the
treatment allocation.
The study was open label: it was not considered feasible to blind participants, carers or site staff.
Sample size
The sample size calculation was based on log-rank test, using Simpson’s rule19 as implemented in Stata
version 11.1 (StataCorp LP, College Station, TX, USA) to allow for the unequal length of follow-up.
The study duration comprised an 18-month recruitment period and a 12-month follow-up period, giving
a maximum follow-up of 30 months and a minimum of 12 months. Assuming control group survival
proportions of 45%, 20% and 10% at the minimum, average and maximum follow-up times, respectively,
a hazard ratio (HR) of 0.45 and an additional 10% loss to follow-up, a total of 108 patients (54 per group)
were needed to ensure a power of 85% using a two-sided type I error of 5%. The control group figures
were conservative estimates based on the sole RCT of NIV,1 which is now considered standard care in the
UK. We estimated the sample size on a conservative (but clinically important) 1-year difference in survival
of 45% versus 70%, which produced the estimated HR of 0.45. It was expected that complete survival
data would be available on all participants recruited, based on previous experience in ALS trials. We did,
however, allow for a 10% loss to follow-up in the sample size calculation.
With regard to QoL data, we expected a low level of missing data due to loss to follow-up. We reviewed
the patients who were initiated on NIV between July 2008 and June 2009 and had maintained contact
with 100% of those patients surviving at 12 months. The appointment of a research nurse at each study
site enabled home visits to collect the QoL data when necessary.
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Early stopping
No interim analyses or early stopping was foreseen. However, in December 2013 the DMEC recommended
that recruitment to DiPALS should cease on safety grounds (discrepancy in survival between the two
treatment arms), and a final decision to stop the trial was made in June 2014. The recommendations and
actions taken are reported fully in results (see Chapter 3).
Statistical methods
Survival
The primary end point was overall survival, defined as the time from randomisation to death of any cause.
Participants were followed up after the last participant’s last visit to determine their final status, and
participants who remained alive were censored on the date last known to be alive. TFS was defined as the
time from randomisation to either death or the placement of tracheostomy, whichever occurred first.
The Kaplan–Meier method was used to visualise survival data and to derive summary statistics of median
survival, interquartile range (IQR) and 95% confidence interval (CI). The median survival was defined as the
point the Kaplan–Meier curve first reached 0.5; if the survival curve did not drop this far, then the median
survival is stated as ‘not reached’. The IQR and the CI for the median are defined analogously. Overall
survival and TFS were compared between the groups using the log-rank test and modelled using Cox
proportional hazards regression using the Efron adjustment for tied survival times and with the
minimisation factors as covariates. The primary analysis was the Cox regression (i.e. adjusted) analysis.
Pretrial modelling found Cox proportional hazards to be the best fit to previous data, but the Cox
proportional hazards assumption was checked by adding time-dependent covariates and graphing scaled
Schoenfeld residuals against time.20 If Cox proportional hazards were found not to fit the data adequately,
an accelerated failure time alternative was fitted and the adequacy of its fit assessed using Q–Q plots.21
Finally, if this too did not fit, the non-parametric restricted mean survival analysis,22 derived from the area
under the Kaplan–Meier survival curves, was used as the basis for summarising the treatment effect.
The overall survival was also reported as of the point at which the DMEC made the decision to (1) suspend
the trial; and (2) terminate the trial with advice to stop pacing. In both of these additional analyses,
participants who were randomised to pacing but did not receive it as a result of the DMEC decision
(two patients) were excluded.
Quality of life
Quality of life was analysed both longitudinally (i.e. over the duration of the trial rather than at individual
time points) and at the end of the study follow-up (12 months). Longitudinal analyses were performed
using generalised least squares regression, with the baseline value and minimisation factors as covariates
and the patient as a random intercept. End-of-study values were analysed using ordinary least squares
regression, with the baseline value and minimisation factors as covariates. For each participant measure,
a complete case analysis was followed by an analysis based on imputed data. First, in the case of
participants for whom data for any visit were missing but data on either side were available (e.g. no
month 2 data but baseline and month 3 data available), the value was imputed using the trapezoid rule.
When absence of data persisted (e.g. because the participant withdrew from the study), the missing data
were imputed using multiple imputation with chained estimation23 using Rubin’s rules and 50 imputations;
the imputation model used the participant’s age, sex, rate of prerandomisation Amyotrophic Lateral
Sclerosis Functional Rating Scale – Revised (ALSFRS-R) score decline, FVC, treatment group and any data at
other time points for the instrument. Missing data arising because of participant death were not imputed
other than for EQ-5D-3L, as the primary objective was to assess QoL among participants while they
remained alive. No attempt was made to impute missing data for the carer QoL.
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The following QoL instruments and measures were collected for participants:
l European Quality of Life-5 Dimensions, three levels: health utility/tariff score and health status
(‘thermometer scale’): the EQ-5D-3L questionnaire comprises six questions. Questions 1–5 are 3-point
scales covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The
responses to these questions map onto a health state in which 1 corresponds to perfect health and
0 to death. Negative values are possible; these are interpreted as a state worse than death. Question 6
is a standalone question that asks the participant to rate their overall state of health today on a
continuous scale between 0 and 10.
l Short Form questionnaire-36 items (version 1): aggregate physical health and aggregate mental health:
the SF-36 was used to derive overall physical and mental health among the participants. Both scores
are scaled such that the general population has a mean score of 50 and a standard deviation of 10,
with higher scores indicating a better QoL.
l Sleep Apnoea Quality of Life Index questionnaire: the SAQLI is a single-domain questionnaire
comprising 14 questions, each scored from 1 to 7: the SAQLI score is the average. When the
questionnaire is incomplete (i.e. < 14 questions are answered), the overall score was defined as
the average, provided at least half of the questions (7 of the 14) had been answered. Higher scores
indicate a better QoL.
The following QoL instruments and measures were collected for carers:
l European Quality of Life-5 Dimensions, three levels: health utility/tariff score and health status
(‘thermometer scale’): the questionnaire was identical to that provided to participants.
l Caregiver Burden Inventory: the CBI is a one-domain questionnaire comprising 24 questions, each
of which is scored from 0 to 4; the overall score is the total of these. Incomplete questionnaires are
scaled up proportionate to the level of missing data unless 12 or fewer questions had been answered.
Higher values indicate better QoL.
All questionnaires were completed at the screening visit and the at subsequent visits (2, 3, 6 and
12 months), the EQ-5D-3L (for participants and carer) was also completed at 9 months.
The analysis of EQ-5D-3L was conducted in two ways. First, an analysis of health status was conducted
using data (possibly imputed) over the duration for which the participant was still alive. Second, the
analysis was performed for all time points but with a score of 0 (which corresponding to a state of death)
used following participant death. The two analyses answer different questions: the first is the health
among survivors; and the second is the health of the population as a whole. The SF-36, SAQLI and CBI
measures were analysed only for the duration in which the participant remained alive.
The EQ-5D-3L was further reported by subgroups (NIV tolerance and bulbar function). Testing for
differential treatment effect between subgroups would necessitate a three-way interaction (treatment
group × subgroup × time), which given the sample size would produce potentially unstable coefficients.
Therefore, the focus here was on within-group summary statistics and graphical displays, separately by
treatment group.
Non-invasive ventilation and diaphragm pacing usage
The original analyses of DPS and NIV usage were based primarily on diary data, augmented by participant
recall at each visit when diary data were incomplete. Later on in the trial we were able to collect NIV
usage data directly from the NIV machine itself, and this was the preferred source of average usage when
available. Average NIV usage was defined as the average number of hours used from the date of NIV
initiation onwards, and average DPS usage was defined as the average daily use from the date of
procedure onwards.
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The relationship between NIV and DPS usage by time point was also assessed. As the relationship between
typical adherence (in hours) and survival was not expected to be linear, fractional polynomials were used to
assess the fits of quadratic and other non-linear relationships.24 Finally, usage was defined in categories.
For NIV we followed the approach of Kleopa et al.,13 who characterised participants as non-adherent
(typical usage < 1 hour per day), low-adherent (typical usage 1 to < 4 hours per day) and good adherence
(typically ≥ 4 hours per day). Adherence to pacing was not categorised as (unlike NIV) normative data on
optimal usage are not available, and also because of the small numbers within each category. Participants
whose NIV or DPS adherence could not be determined based on the available data were excluded from
these exploratory analyses.
Health resource use
Health resource use was summarised as the use of each of the following:
l health service use – hospital admission, emergency department attendance, minor injury clinic or walk-
in centre or general practitioner (GP)
l respiratory device – cough assist machine, breath stacking, suction
l health and social care – physiotherapist, occupational therapist, other
l additional care/support – formal (e.g. home help) and informal (e.g. family/friends).
Additional outcomes: Amyotrophic Lateral Sclerosis Functional Rating Scale
and respiratory function
In the light of the early stopping, the TSC requested additional respiratory function data be collected to
augment that which was already collected at baseline (and for DPS, immediately pre surgery). Specifically,
we wished to assess (1) whether or not the groups were comparable at baseline; (2) whether or not
decline among the NIV plus DPS group appeared more pronounced in the postsurgery period than in the
NIV group; and (3) the trajectory across time in general to see if it offered any other clues with which to
explain the findings. We were able to obtain data at some, but not all, sites for FVC, arterial carbon
dioxide and ALSFRS-R.
Adverse events
Adverse events were coded by the chief investigator blind to the participant’s treatment group. AEs were
summarised for each AE category and, overall, as the number and percentage of patients affected and as
the number of events in total (as a patient may have more than one occurrence of the same AE). The
summary was repeated for SAEs. All AEs that were adjudged related to pacing (either probably or
definitely) are listed as recorded. Summaries are presented based on the randomised group (i.e. intention
to treat), but any NIV plus DPS group AEs reported by non-implanted participants were highlighted.
General analysis considerations
All treatment comparisons use the NIV-only group as the reference (comparator); all statistical exploratory
tests of main effects were two-tailed with α= 0.05; and all CIs were two-sided, with 95% intervals.
A permutation test was used to confirm the p-value from the primary end point.25 As interaction tests
have low statistical power, consideration was given to p-values below 0.1 when testing interactions
(treatment × centre and treatment × subgroups).
Analyses were by intention to treat, with preplanned secondary analyses of overall survival based on
protocol adherence and NIV usage. Analyses were undertaken using Stata version 12.1 and SAS 9.4
(SAS Institute Inc., Cary, NC, USA).
METHODS
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Economic evaluation
Prior to the trial commencing, a modelling exercise was undertaken to assess the feasibility that pacing
could be cost-effective at standard willingness-to-pay thresholds for end-of-life care. This modelling
confirmed that pacing would be cost-effective if the trial were to demonstrate a treatment effect of similar
magnitude as demonstrated by the SSPB cohort in comparison with historical data. A full cost–utility
analysis was planned for this trial, but following the early termination of the trial the chief investigator and
funder agreed that this was no longer necessary.
Research governance
Sponsorship
Sheffield Teaching Hospitals NHS Foundation Trust sponsored the trial (reference STH15625).
Oversight committees
Oversight committees were established to govern study conduct: Trial Management Group (TMG),
TSC and DMEC. The trial was conducted in accordance with CTRU’s SOPs, with committees convening at
appropriate intervals as dictated by both study requirements and SOPs (see Acknowledgements).
The TMG consisted of the chief (chairperson) and principal investigators (PIs) and key staff within the
CTRU, and this committee met monthly via teleconference during trial recruitment and follow-up. An
independent consultant neurologist chaired the TSC, other external members comprising a respiratory
clinical expert, an independent statistician and two lay representative/patient and public involvement (PPI)
members. All TSC members were appointed by the Health Technology Assessment programme. The DMEC
consisted of an independent statistician, clinical neurologist (chairperson) and consultant neurologist.
The TSC received formal recommendations from the DMEC.
Research Ethics Committee
Cambridge Central National Research Ethics Service committee (reference 11/EE/0026) approved the trial
and all subsequent amendments.
Medicines and Healthcare products Regulatory Agency
The intervention was used within its licence for intended use with appropriate Conformité Européenne
mark documentation. Medicines and Healthcare products Regulatory Agency approval was not applicable.
Serious adverse events
Adverse events were reported in accordance with the CTRU’s AEs and SAEs SOP (PM004) and
supplementary study-specific guidance approved by the sponsor.
Expected disease progression was specified in the protocol as an expected AE that did not need to be
reported. Other expected AEs were listed with the requirement to report: chest infection requiring the use
of antibiotics, an infection at the site where DPS was fitted and revision of the DPS.
Protocol non-compliances
Protocol non-compliances were reported in accordance with CTRU’s non-compliance SOP (PM011),
but also additional study-specific guidance approved by the sponsor. Non-compliance categories were
prespecified with the trial sponsor and are listed below. Major non-compliances were reported to the
sponsor and immediate action taken; minor non-compliances were recorded by the CTRU and reported
periodically to trial oversight committees and the sponsor.
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Prespecified major non-compliances:
l Participants found to be ineligible following randomisation.
¢ Action: participant withdrawn.
l Consent procedure or good clinical practice not followed correctly (e.g. patient not consented).
¢ Action: participant reconsented.
Prespecified minor non-compliances:
l completion of any baseline data post randomisation
l minor errors on the consent form
l patient did not receive allocated treatment
l time-specific windows stated in the protocol missed (e.g. participant not randomised or informed of the
arm allocated to within 7 days of screening).
Monitoring and reporting
The level and type of monitoring was informed by a risk assessment conducted during the set-up period
of the study. A Data Monitoring and Management Plan and a Monitoring Plan were written and agreed
with the sponsor prior to the start of trial recruitment. On-site and central data monitoring activities
were completed to ensure participant safety, protocol compliance and data integrity.
Central monitoring
Data were centrally monitored based on parameters specified in the Data Monitoring and Management
Plan. Checks included point of entry and post-entry validation checks and verification of data entry.
Site monitoring
The trial study manager completed a site initiation and training visit with research staff at sites prior to
participant recruitment. Subsequent visits were conducted after sites had started recruitment to check the
ongoing suitability of the site and to perform source data verification. Monitors checked data recorded on
the case report form against medical records, discussed recruitment and issues with intervention delivery,
SAEs/AEs, resolution of data queries and maintenance of the site file. A final closeout visit was performed
at each site at the end of participant recruitment, scheduled once data collection was complete.
Monitoring issues were initially highlighted and discussed with sites, and remedial actions sent to the
research nurse and PI. Any problem themes identified and specific issues with sites were discussed with
the chief investigator and when required escalated to the sponsor, TSC and DMEC.
Reporting
The trial team were required to submit annual reports on trial progress, data completion rates, and safety
and protocol compliance to the REC; and 6-monthly reports to the funding body.
Important changes to methods after trial commencement
Details of substantial amendments submitted to the REC, which were important changes to trial
methodology, are listed below.
November 2012: amendment 5 (minor)
Protocol version 3 specified that participant be initiated onto NIV (in both arms) within 1 to 2 weeks of
randomisation. The protocol was amended to allow sites to initiate NIV as per usual clinical practice after
the participants enrol onto the trial and not necessarily before DPS implantation. This distinction was
necessary as, although participants were experiencing respiratory insufficiency based on their clinical
METHODS
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assessments, clinicians wished to initiate NIV when participants were more symptomatic in line with their
standard practice. The trial TSC were in agreement with this rationale. The protocol was also amended
to allow DPS implantation to ideally occur within 8 weeks of randomisation based on the practical
feasibility of getting participants into theatre.
June 2013: amendment 6 (substantial)
The protocol was clarified to state that blood gases were required only to assess PaCO2 levels (inclusion
criteria 4e); if alternative respiratory measures were used for eligibility assessment, blood gases were not
required. A member of Synapse Biomedical (manufacturers of the device) was present at each operation as
stated in the protocol; however, as sites (surgeons, research nurses and clinicians) gained experience and
became competent in the use of the device, it was felt appropriate that the protocol be amended.
This change was also reflective of standard practice for having DPS fitted worldwide. The wording in the
protocol was amended to:
A member of Synapse will attend each procedure until sites become competent with use of the device
to manage patients independently. The local site PI will be responsible, after liaising with local site
staff, deciding when site staff are competent in performing the intervention without any input from
Synapse. The Surgeon at the site will self-certify their competency to perform the operation
independently at this stage.
Although this change was approved by the REC, none of the surgeries was performed independently and
a member of Synapse Biomedical was present at each operation to provide verbal assistance during the
procedure. The protocol was amended to allow patients not to start pacing until the 1-week postoperative
appointment to allow patients to adjust to having the device fitted in the immediate postoperative period
and to ensure standardisation of the process across sites. This amendment also added both postal or
e-mail options to optimise data collection when it was difficult for patients/carers to attend in person.
October 2013: amendment 7 (substantial)
The protocol was amended to allow respiratory tests up to 2 weeks pre consent to be used for eligibility
assessment. This was felt an appropriate cut-off point to not overburden participants with repeat tests
while still ensuring that respiratory function would not have significantly changed. As part of this
amendment, the instructions on the participant diaries were changed and a newsletter template was
approved to both provide more clarity on how to collect the data but also to emphasise the importance of
doing so.
November 2013: amendment 8 (minor)
The previous protocol allowed self-reported NIV data to be collected from participants. As the study
progressed, it was apparent that more detail was required to build a picture a more accurate picture of NIV
use including NIV data collected directly from the NIV machines. The protocol was amended to allow
NIV usage data from the machines to be collected.
January 2014: amendment 9 (substantial)
Following the DMEC’s recommendation to the TSC, recruitment into the trial was halted and participants
randomised to DPS but who had not undergone surgical implantation were not to do so. Otherwise,
participant follow-up was to continue as planned for those already in the trial.
June 2014: amendment 10 (substantial)
Researchers clarified the protocol to allow sites to initiate NIV post consent rather than post randomisation.
As the screening process could take a few weeks, it was accepted that NIV could be initiated based on
clinical need for participants in this period between consent and randomisation. The collection of routine
respiratory and ALSFRS-R data was added to the protocol during the 12 months of participants’
involvement in the trial. This was to aid the analysis about the rate of participant deterioration over the
course of the trial.
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June 2014: amendment 11 (substantial)
Following unblinded data review on 23 June 2014, the DMEC recommended that participants in the pacing
arm should be advised to discontinue using the DPS unless they specifically requested otherwise. All
participants should remain under follow-up as scheduled. A specific SOP detailing discontinuation of DP
at sites was written and submitted as part of the amendment, together with a GP letter and letters for
participants still in the trial (one for each arm) to inform them of this decision and what to do next.
Provision was made such that any participant wishing to continue using the DPS would be allowed to do so.
September 2014: amendment 12 (substantial)
A substantial amendment was submitted to allow central University of Sheffield researchers to interview
site staff in relation to running the DiPALS trial locally. The interviews explored the experiences of the
research staff recruiting participants, particularly with regard to the population (ALS participants at a later
stage of disease); intervention (surgical intervention involving general anaesthesia, compliance with the
intervention and standard care); and other barriers and facilitators to recruitment.
Patient and public involvement
Patient and public involvement was sought throughout the trial. The Sheffield Motor Neurone Disease
Research Advisory Group (SMNDRAG), an independent research advisory group, was approached and
agreed to be involved at an early stage. The SMNDRAG was established in 2008 following the principles of
INVOLVE.26 The group comprises members of the public, including several carers of ALS patients, patients
and other lay individuals who responded to the call for members. Research training is provided to all
members of the public that volunteer for the SMNDRAG as part of their induction and ongoing support.
The SMNDRAG has been a valuable part of the DiPALS trial, collaborating as part of the research team at
all stages of the research process.
Proposal development
The SMNDRAG was consulted about the concept, research question and design at the proposal application
stage. SMNDRAG members collaborated in writing the proposal, with particular input to the lay summary.
They also suggested modifications to the protocol; an example of this was the addition of methods to
capture carer experience, using both CBI and qualitative interviews.
During the trial
Following the funding decision, the SMNDRAG was involved during the development of the trial protocol
and associated essential documents. Members were asked periodically to comment on key changes to
participant materials when required.
Study oversight
A PPI member from the SMNDRAG was invited to attend the monthly TMGs for day-to-day running of the
trial. The trial TSC had two independent members (PPI and lay person) to assist in governing trial conduct
and provide advice from the patient/lay perspective.
Study dissemination
At the end of the study, the SMNDRAG members assisted in dissemination of the trial results through
networks that have been established regionally and nationally, and in reviewing the plain English summary.
METHODS
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Chapter 3 Early stopping
T rial recruitment was stopped earlier than planned on safety grounds. The recommendations from theDMEC were accepted in full, and the subsequent changes to trial conduct and recruitment are detailed
in this chapter.
Recruitment suspension
The fourth DMEC meeting was held on 16 December 2013. The ‘open’ part of the meeting discussed trial
progress with both internal and external DMEC members. This was followed by a ‘closed’ meeting when
the external, independent members reviewed unblinded safety data.
Following the closed meeting, the chairperson of the DMEC contacted the chief investigator on
18 December to recommend that the trial suspend recruitment temporarily based on safety grounds, citing
a discrepancy in survival between the two arms. In doing so, the DMEC acknowledged that the sample
size was relatively small (74 randomised, 24 deaths at the point of this recommendation), and that their
decision would be reviewed as additional data became available.
The DMEC provided the following response:
The DMEC has reviewed the unblinded data on survival in the DiPALS study and the members of the
Committee are unanimous in recommending that recruitment should cease as soon as practicable for
reasons of safety, that monitoring of safety and survival should continue, and that the DMEC should
review the updated survival data at the end of February 2014, and periodically thereafter.
Suspension of recruitment did not constitute an ‘urgent safety measure’.
In summary, the DMEC recommended that:
l recruitment be suspended with immediate effect
l implantation of new pacing devices be suspended
l other aspects of the trial remain unaltered; in particular, patients in the pacing arm should be
encouraged to continue using their device.
The CTRU suspended the online randomisation system on the same day to ensure that no further patients
were recruited to the trial. The TMG (PIs, co-investigators, research nurses and relevant members of the
CTRU) were all notified of this decision immediately (18 December 2013). All planned surgeries for the DPS
were cancelled. The PIs and chief investigator discussed the key message to give to any concerned trial
participants while still remaining blinded to the data.
The TSC convened on 20 December 2013 to discuss the implications of this decision and their concerns
that the data had not been thoroughly scrutinised. These included the consideration of centre effects;
the effect of patient withdrawal and non-implantation with the device; chance; and non-compliance with
either NIV or DPS. A second unblinded report was produced and circulated to only the external,
independent DMEC members that incorporated analyses to ensure all these issues were considered.
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A joint TSC and DMEC meeting was held on 13 January 2014 to allow all members to present any
remaining concerns before responding to the DMEC. The TSC and study team remained blinded to trial
results. The DMEC upheld its initial decision by providing the following response to the additional
data analyses:
The DiPALS DMEC members, having reviewed the updated unblinded report and having considered
the points raised during discussion with the TSC, remain unanimous in their advice that recruitment
into the DiPALS trial should cease, but that follow-up should continue. This advice is based on analysis
of the primary end point (patient survival during the course of the trial). The DMEC considers that
secondary analyses are unlikely to alter the safety concerns raised by the primary intention-to-treat
analysis. The DMEC will be happy to consider further reports and to provide advice as required.
The TSC jointly agreed and communicated its agreement with the DMEC to suspend recruitment to the
trial team late on 15 January 2014. The TSC requested that the DMEC continue to review unblinded data
every 3 months to capture any further changes that would warrant discontinuation of the use of the DPS
for participants in follow-up.
Informing the Research Ethics Committee
The acting trial manager informed the REC on 6 January 2014 of the initial decision to suspend
recruitment, with a further notification to the REC on 15 January 2015 after the final TSC decision.
A formal substantial amendment was submitted to the REC on 5 February 2014. A full account
(see Recruitment suspension) was provided to the REC as part of the amendment. The sponsors of
the trial (Sheffield Teaching Hospitals) approved the amendment, and sought direct assurance from the
chairperson of the DMEC that participants already in the trial would continue to be followed up as per
protocol, that is would continue to receive the intervention as prescribed. The CTRU informed the
REC that as the central study team (chief investigator, and study and data managers) and all site study staff
(PIs and research nurses) remain blinded to the data disclosed in the closed part of DMEC they would be
unable to provide any further detail than that provided. The REC was asked to contact the chairperson
of the DMEC for any further assurance regarding the decisions made.
As trial participants remained in follow-up and continued to receive the DPS intervention, they were not
informed of the decision to halt recruitment of new participants into the trial.
Withdrawal of participants from diaphragm pacing system
The DMEC continued to review unblinded data and the next meeting was convened on 24 March 2014.
The DMEC reviewed further deaths in each group and other safety and tolerability data. The DMEC
requested that the chief investigator consider a pathway for formal participant withdrawal from the
intervention, which would need to be ethically approved should this be required. Following this meeting
there was no change in the study status.
The subsequent DMEC meeting was held on the 23 June 2014. The following recommendations were
made by the DMEC after the closed session:
l As the survival data suggest that DP poses an ongoing safety risk compared with standard care, in the
interest of safety, DPS should be stopped in all participants using the approved process.
l Participants, however, subject to consent, should continue to be followed up and data acquisition
should continue until the planned end of the trial (December 2014).
The DMEC also wished to review the statistical analysis plan (see Appendix 13) prior to database lock and
advised that the trial team (chief investigator, PIs and other central study staff) remain blinded to the data
prior to final database lock and analysis. The DMEC advised that the study group inform the REC and
discuss the withdrawal procedure with PIs and then withdraw patients as soon as practicably possible.
EARLY STOPPING
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Formal stopping of recruitment
The recommendation to formally stop recruitment was made by the DMEC in June 2014. This time, its
recommendations went further:
l Participants in the pacing arm were to be informed of the concern and advised to cease use of their
device forthwith (unless the patient and their clinician believed there were just grounds to do otherwise).
l Trial follow-up was to continue until all participants had either died or completed the 12-month
follow-up.
l The TSC and trial team were to remain blind to the outcome data until this time.
Informing Research Ethics Committee, participants and investigators
The chief investigator and study manager drafted the following documentation to inform trial participants
still in follow-up within the trial about the decision to stop pacing (see Appendices 14–17):
1. stop pacing participant letter – DPS arm
2. stop pacing participant letter – NIV arm
3. stop pacing GP letter – DPS arm
4. pacing discontinuation SOP.
A TMG meeting was held with study PIs the following day (24 June 2014) to review all drafted documents
and agree the process. It is important to note that all the study team remained blinded to the data at this
stage. Any modifications suggested to the process or documents were agreed at the meeting. Amended
documents were submitted to the REC as part of a substantial amendment on 27 June 2014. Prior to this,
the study manager sought confirmation about the nature of risk posed by the intervention; if there was an
immediate risk, then urgent safety measures would be required. The DMEC confirmed that there was no
evidence to suggest any immediate risk to participants in the DPS arm and, therefore, a more gradual
approach was appropriate.
Research Ethics Committee approval was received on 4 July 2014. Individual research and development
departments are required to approve a substantial amendment or raise no objections within 35 days of its
valid receipt. Researchers did not wish to wait in order to implement this amendment and, therefore, the
trial manager e-mailed, telephoned and spoke with each research and development department to
approve the amendment to avert any delays in its implementation. The trial manager informed each PI
and research nurse as soon as local approval was received. The chief investigator asked site PIs to use the
approved documentation and process to directly inform participants of the study status and answer any
questions that arose. The study manager asked to be notified of the status of each participant in the DPS
arm after the conversation with the participant via the return of the participant discontinuation checklist.
The Motor Neurone Disease Association was informed of the advice to stop pacing. This was
communicated to motor neurone disease patients via their website. The DiPALS trial website was updated
to inform potential participants that the study was no longer in recruitment.
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Chapter 4 Trial results
Recruitment and participant flow
In total, 74 participants (37 per arm) were randomised between 5 December 2011 and 18 December 2013,
when the DMEC recommended that recruitment cease. Study follow-up concluded in December 2014,
by which time 47 patients had died; one patient was last followed up in August 2014, with the remaining
26 known to be alive in December 2014 (Figure 2).
Assessed for eligibility 
(n = 759)
Excluded
 (n = 685)
• Ineligible, n = 539
   • Not yet in respiratory failure, n = 160
   • FVC / SNIP too low, n = 93
   • Prior NIV, n = 74
   • Not on riluzole, n = 23
   • Unconfirmed MND diagnosis, n = 21
   • Other / NK, n = 168
• Declined to participate, n = 95
• In screening at trial termination, n = 51
Lost to follow-up for primary outcome 
(n = 0)
Allocated to NIV 
(n = 37)
• Received allocated intervention, n = 37
Lost to follow-up for primary outcome 
(n = 0)
Discontinued DP intervention 
subsequent to implantation 
(n = 5)
• DMEC recommendation, n = 2
• Patient choice, n = 2
• Technical problems with device, n = 1
Allocated to DP plus NIV 
(n = 37)
• Received allocated intervention, n = 32
• Did not undergo surgery, n = 5
   • DMEC recommendation, n = 2
   • Patient choice, n = 2
   • Rapid decline in respiratory function, n = 1
Analysed 
(n = 37)
Allocation
Analysed 
(n = 37)
Analysis
Follow-up
Enrolment
Randomised 
(n = 74)
FIGURE 2 Trial profile (CONSORT diagram). MND, motor neurone disease; NK, not known.
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Baseline data
A total of 74 participants were allocated (37 to each arm). The characteristics of the participants are
presented in Table 2. Participants were predominantly male with sporadic (usually limb) onset and with
mild bulbar impairment (74%). Despite age being included as a minimisation factor, the NIV plus DPS arm
was slightly older (average 60 vs. 54 years), a consequence of most participants falling into the middle
category of age 40–79 years; this imbalance was addressed in all comparisons, however, as all prespecified
analyses included age as a covariate (continuous, rather than the categorisation used for the purpose
of minimisation).
TABLE 2 Baseline data
Variable
Trial arm
NIV plus DPS (N= 37) NIV (N= 37)
Centre, n (%)
Leeds 2 (5) 5 (14)
London 1 (3) 1 (3)
Manchester 6 (16) 4 (11)
Newcastle 6 (16) 2 (5)
Oxford 11 (30) 13 (35)
Plymouth 3 (8) 3 (8)
Sheffield 8 (22) 9 (24)
Age (years)a
Mean (SD) 60 (9.7) 54 (12.0)
Median (range) 61 (34–83) 53 (23–76)
Trial subgroup, n (%)
< 40 years 1 (3) 3 (8)
40–79 years 35 (95) 34 (92)
≥ 80 years 1 (3) 0
Sex, n (%)a
Male 29 (78) 29 (78)
Female 8 (22) 8 (22)
Bulbar score (%)a
Mild (9–12) 26 (70) 29 (78)
Moderate (5–8) 8 (22) 6 (16)
Severe (0–4) 3 (8) 2 (6)
FVC (%)a
Mean (SD) 66.1 (12.3) 64.6 (12.1)
Median (range) 62.5 (51–105) 62.5 (42–97)
Trial subgroup, n (%)
50–59% 13 (35) 16 (43)
60–69% 12 (32) 10 (27)
≥ 70% 11 (30) 10 (27)
Missingb 1 (3) 1 (3)
TRIAL RESULTS
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Primary outcome (overall survival)
Primary overall survival analyses
The Kaplan–Meier curve for overall survival is presented in Figure 3. The median survival was 11.0 months
(95% CI 8.3 to 13.6 months) in the pacing arm and 22.5 months in the control arm. As the upper bound
of the Kaplan–Meier survival curve never reached 50%, the upper limit of the 95% CI is unknown: the
lower bound is 13.6 months. The HR (adjusting for minimisation covariates) was 2.27 (95% CI 1.22 to
4.25; p= 0.01), indicating the risk of death at any point in time was higher in the NIV plus pacing arm
than in the control arm. A permutation test approach, as recommended by Scott et al.,25 produced a
p-value of 0.013 confirming the statistical significance of this difference.
TABLE 2 Baseline data (continued )
Variable
Trial arm
NIV plus DPS (N= 37) NIV (N= 37)
ALS onset type, n (%)
Sporadic 34 (92) 35 (95)
Familial 3 (8) 2 (5)
ALS onset site, n (%)
Limb 26 (70) 28 (76)
Bulbar 10 (27) 6 (16)
Respiratory 1 (3) 1 (3)
Mixed 0 2 (5)
ALS diagnosis, n (%)
Clinically definite 26 (70) 22 (59)
Clinically probable 7 (19) 9 (24)
Clinically probable, laboratory supported 4 (11) 6 (16)
Time from symptom onset to randomisation (months)
Mean (SD) 22 (18) 22 (15)
Median (range) 17 (4–89) 18 (3–66)
Trial subgroup, n (%)
< 12 months 12 (32) 14 (38)
12–24 months 14 (38) 12 (32)
≥ 24 months 11 (30) 11 (30)
ALSFRS-R score
Mean (SD) 32.9 (7.4) 33.7 (6.5)
Median (range) 33 (21–46) 35 (21–46)
Rate of ALSFRS-R score decline/monthc
Mean (SD) 0.99 (0.68) 0.94 (0.71)
Median (range) 0.80 (0.02–2.92) 0.92 (0.20–3.72)
SD, standard deviation.
a Minimisation factors.
b Two participants in whom no FVC data were recorded; their SNIP results were 53 cmH2O (pacing) and
34 cmH2O (control).
c Defined as (48 – baseline ALSFRS-R score)/(number of months since onset). Forty-eight is the maximum possible
ALSFRS-R score and is the assumed score at onset. The equation therefore represents the average change per month.
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Sensitivity analyses were undertaken to assess the consistency of findings to different covariates and to
different models. First, we allowed for between-site differences via a stratified log-rank test in which
the strata comprised the seven hospitals. The findings from doing this were not materially changed.
There was, however, evidence of non-proportionality of the hazards of the two groups, as detected by the
Grambsch–Therneau test20 for the correlation between residuals and time (ρ= –0.31; p= 0.03). In other
words, although overall NIV plus DPS was associated with a twofold increase in hazard, the impact was
greater in early months and smaller among longer-term survivors. Two alternative modelling approaches
were fitted: first, an accelerated failure time model (in which the time, rather than hazard, is modelled);
and, second, a non-parametric restricted mean survival time, in which the difference in mean survival is
estimated based on the area between the Kaplan–Meier curves.22 The findings from the sensitivity analyses
analysis are presented in Table 3. Overall, the magnitude of the survival deficit in the NIV plus DPS group
was remarkably consistent, with survivorship always significantly lower in the NIV plus DPS group.
Overall survival at Data Monitoring and Ethics Committee intervention
The DMEC did not prespecify rules for stopping because of safety, preferring to use clinical judgement
about participant outcomes as a whole. Nevertheless, its recommendations were based primarily on overall
survival, and for reference we present overall survival as of the following dates:
l 10 December 2013 (the date that data were seen by the DMEC, when it recommended suspension of
recruitment and implantation)
l 10 June 2014 (the date that data were seen by the DMEC, when it recommended participants in the
NIV plus DPS arm should cease pacing).
The statistical significance of the overall survival difference varied markedly during the data collection
phase, both across time and also according to which of the aforementioned models were used to derive it.
Nevertheless, as shown in Table 4 and Figures 4 and 5, overall survival was significantly worse in the NIV
plus DPS group at both time points.
Subgroup analyses of overall survival (preplanned)
We prespecified three subgroup analyses: (1) by NIV tolerance, based on estimated average NIV usage;
(2) by bulbar function, as derived from the ALSFRS-R questionnaire; and (3) a per-protocol analysis
excluding participants who were inappropriately randomised or who did not adhere to NIV and/or pacing
(if that was their randomised allocation).
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TABLE 3 Sensitivity analyses
Method of analysis
Trial arm
ComparisonNIV plus DPS NIV
Cox proportional hazards regression Deaths per person-year follow-up HR (95% CI) p-value
Log-rank (univariate) 0.74 0.37 2.24 (1.30 to 4.19) 0.005
Log-rank (stratified by centre) – – 2.02 (1.21 to 3.84) 0.012
Cox regression (univariate) – – 2.28 (1.27 to 4.10) 0.006
Cox regression (including minimisation factors
as covariates)
– – 2.27 (1.22 to 4.25) 0.012
Accelerated failure time regression Median survival time (months) Time ratio (95% CI) p-value
Gehan–Wilcoxon test (univariate) 11.0 22.8 – 0.002
Gehan–Wilcoxon test (stratified by centre) – – – 0.029
Log-normal regression (univariate) – – 0.52 (0.36 to 0.77) 0.001
Log-normal regression (including minimisation
factors as covariates)
– – 0.52 (0.35 to 0.77) 0.001
Restricted mean failure time
Mean survival time over first
30 months Difference (95% CI) p-value
Univariate 13.7 20.6 –6.9 (–11.4 to –2.4) 0.003
Including minimisation factors as covariates – – –6.8 (–11.5 to –2.2) 0.005
TABLE 4 Statistical significance of the overall survival difference during data collection
Data collection time point
Trial arm, number (%) of deaths
Intention-to-treat comparison
(univariate)NIV plus DPS NIV
All patients
(n= 37)
Excluding
non-implanted
(n= 32)
All patients
(n= 37) HR (95% CI)a p-value
As of 10 December 2013 16 (44b) 14 (44) 8 (22b) 2.45 (1.05 to 5.74) 0.039
As of 10 June 2014 23 (62) 21 (66) 11 (30) 2.73 (1.33 to 5.60) 0.006
At end of study 28 (76) 26 (81) 19 (49) 2.28 (1.27 to 4.10) 0.006
a Univariate Cox regression.
b Thirty-six participants in each arm at this time. A further two participants were randomised between production of the
database report and the DMEC meeting (18 December 2013). The number of participants implanted remained at 32.
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
The results of these are given in this section. In all cases the results were not adjusted for other covariates,
as the small number of participants in each subgroup means that more complex models are likely to be
unstable. Subgroup analyses were by univariate Cox regression, and tests of interactions were derived by
adding treatment, subgroup and their interaction to the model. It should also be noted that small
subgroup sizes results in wide CIs and low statistical power both for the main effects and interactions.
Overall survival by baseline bulbar function
The subgroup analysis by bulbar function was originally defined to look at survival in severe (functional
score of 0–4) and mild/moderate (functional score of 5–12) separately. As all bar five participants were in
the latter group, we have chosen to split the mild and moderate subgroups out, but retain severe bulbar
function as its own (small) category.
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FIGURE 5 Survival at 10 June 2014.
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Overall survival was inferior in the NIV plus DPS arm in both mild and moderate subgroups, although the
difference was statistically significant only in the former. There were too few participants in the severe
subgroup to allow a meaningful interpretation to be made. Overall, there was little evidence of a
differential effect of DP according to bulbar function with a non-significant p-value for the interaction
between bulbar function and group (likelihood ratio test χ2(2)= 3.44; p= 0.18) (Figure 6).
Overall survival by non-invasive ventilation tolerance
The subgroup analysis by NIV use was again originally defined to look at survival in two subgroups: NIV
tolerant (≥ 4 hours typical daily use) and NIV intolerant (< 4 hours). Post hoc, we have split the latter
category further into low NIV use (1–3.9 hours daily, which might confer some benefit) and non-NIV use
(< 1 hour daily, which confers virtually no benefit). The rationale is to allow better assessment of the
relationship between pacing and outcome. Pacing has been suggested as possibly having particular benefit
among patients who do not tolerate NIV, and this analysis allows us to put that hypothesis to the test.
Moreover, the difference in survival may (theoretically) be attributed to participants in the NIV plus DPS
arm using pacing in place of NIV; this allows us to compare users within each NIV use subgroup.
We categorised average daily NIV use into < 1 hour, 1–3.9 hours or ≥ 4 hours in order to assess whether
or not the difference between groups in overall survival was similar. The Kaplan–Meier graphs are shown
in Figure 7. In six participants there were inadequate data from which to assess NIV usage, and small
numbers hamper interpretation, but survival in the NIV plus DPS was not superior to NIV alone in any
subgroup, with the largest difference (in favour of NIV) among the subgroup of participants who did not
use NIV. As with bulbar function there was no evidence of a differential effect according to NIV use at
conventional statistical levels (likelihood ratio test χ2(2)= 4.14; p= 0.13).
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FIGURE 6 Overall survival by bulbar function. (a) Mild bulbar impairment; (b) moderate bulbar impairment; and
(c) severe mild bulbar impairment. (continued )
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FIGURE 6 Overall survival by bulbar function. (a) Mild bulbar impairment; (b) moderate bulbar impairment; and
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Per-protocol analysis of overall survival
Protocol compliance was based on excluding participants who:
l were randomised in error (i.e. in breach of inclusion/exclusion criteria)
l did not tolerate NIV (< 4 hours’ average daily use)
l did not undergo successful DP implantation
l were non-users of DP.
This subgroup was very similar to that shown in the ‘tolerant’ (≥ 4 hours) subset in subgroup analysis.
No participants were erroneously randomised and only one non-user of the pacing device was NIV
tolerant, meaning that the total number included reduced from 34 to 33. The HR for NIV plus DPS
compared with NIV in this subgroup was 1.92 (95% CI 0.81 to 4.56; p= 0.141).
Non-invasive ventilation and pacing usage
Non-invasive ventilation use
Non-invasive ventilation was initiated in 70 out of 74 patients. In total, 57 patients were initiated within
2 weeks of randomisation, a further six within 1 month and the remaining 7 between 3 and 11 months.
NIV usage was similar between the two groups (Table 5 and Figure 8).
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Pacing use
Five pacing group participants did not undergo surgery because of a rapid decline in respiratory function
below the safety threshold for surgery (n= 1), patient choice (n= 2) and the DMEC intervention (n= 2);
and a sixth patient chose to stop pacing within 1 month of implant following technical problems with the
device. All participants who went to surgery had a successful implantation, with a stimulatable diaphragm.
When used, the median daily usage was 4.6 hours (IQR 3.0–8.4 hours). Participants pacing were largely
able to achieve the target pacing settings within 15 days of surgery and continued to successfully titrate
over the course of the study as per the study protocol. Pacing was well tolerated, with only two patients
choosing to formally discontinue pacing after implantation, one at 6 months and one at 12 months.
The DP settings and usage are described in Table 6–8.
TABLE 5 Average daily NIV usage after initiation
Variable
Trial arm
NIV plus pacing (n= 37) NIV (n= 37)
Number of patients with data 34 34
Average daily usage (hours)
Mean 5.2 4.8
Median (IQR) 3.2 (0.5–8.2) 4.6 (0.0–7.8)
Number (%) by subgroup
< 1 hour 9 (26%) 11 (32%)
1–3.9 hours 9 (26%) 5 (15%)
≥ 4 hours 16 (47%) 18 (53%)
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FIGURE 8 Average daily NIV usage after initiation.
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Overall survival by non-invasive ventilation and pacing
The relationship between overall survival and NIV use (categorised as non-use, low use and tolerant over
the study period) is covered further in this section. Furthermore, the use of overall survival and NIV use in
relation to pacing is investigated in more detail. The role of post hoc and exploratory analyses is to attempt
to understand the unexpectedly poor survival experienced by participants in the NIV plus DPS group.
Non-invasive ventilation use and overall survival
The problems in evaluating the association between therapeutic regimens and patient outcomes in an
uncontrolled, observational setting are well documented. Using NIV is generally accepted as beneficial,27
but the extent to which a participant uses it depends, to a degree, on prognosis. A patient who uses NIV
at low levels may do so because their respiratory physician considers them well enough, or they consider
themselves well enough, to have no need for high levels of use. Conversely, ALS patients often use NIV at
high levels (≥ 12 hours per day) towards the end of their life. There are other factors besides this which
impact on NIV use, but the aforementioned factors illustrate how the true impact of NIV is confounded by
prognosis and can thereby be underestimated. With this in mind, the overall lack of association between
NIV use and survival in the remainder of this section should not be taken as evidence against NIV being
beneficial. Rather, this section attempts to assess whether or not NIV use gave rise to differential treatment
effect and, crucially, whether or not some participants in the NIV plus DPS group used pacing in place
of NIV.
We also note the difficulties in quantifying NIV use. In some cases there was a lag between NIV initiation
and regular use, and in a handful of cases several months passed between initiation and regular use. It
could be argued that the analysis should take NIV use starting from the date of first regular use, but the
limitation of doing so is that ‘regular’ use is not unequivocally defined. Some patients started NIV at low
levels (1–2 hours per day), whereas others used NIV on trial basis, only to stop (sometimes for several
months) before recommencing. Furthermore, the participant diary data were in many cases not recorded in
sufficient detail (completeness) to allow a date of ‘regular’ use to be determined.
TABLE 8 Pacing usage
Variable NIV plus DPS (n= 37)
Number of patients using pacing 31
Non-users 6
Did not undergo surgery 5
Withdrew with minimal usage following technical problems 1
Time to surgery (n= 32 implanted), n (%)
Within 14 days 5 (16%)
15–28 days 12 (38%)
29–56 days 10 (31%)
> 56 days 5 (16%)
Average daily usage when used (hours)
Mean 6.2
Median (IQR) 4.6 (3.0 to 8.4)
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Non-invasive ventilation use in the 12-month follow-up period
We first looked at NIV from the point of initiation to the end of the 12 months’ follow-up or death,
whichever occurred first. Data were available for 68 of the 74 participants over the study duration.
The primary motivation, however, is not to quantify the association between NIV and survival per se, but to
investigate whether or not the difference between the randomised NIV plus DPS and NIV arms may be
affected by NIV rather than pacing alone.
The problem in visualising survival data is that the survival times are censored for a proportion of the
participants. The relationship between NIV use and survival can be displayed graphically only if some
assumptions are made as to what the censored times would have been, had they been observed. There is
necessarily considerable uncertainty in doing so. For the purpose of displaying the data in graphical form
we followed the approach proposed by Royston and Parmar22 to estimate the underlying (but unobserved)
survival times based on each individual’s censored survival time, treatment group and prognostic
covariates. A Q–Q plot of the data showed the log-normal survival distribution to give a reasonable fit to
the data; therefore, a truncated log-normal regression model was fitted. From this, the overall survival for
each individual was being estimated based on their predicted mean survival, their censored survival time,
and the root-mean-square error of the model. We fitted two models with minimisation covariates also
included in both: first, for all patients and then second, within each group separately. The estimated
survival was taken as the average of these two predicted times.
It is important to note that we estimate the survival times only for the purpose of visualising the
relationship between NIV, and not for the analysis itself. In all cases, the graphical display distinguishes
estimated survival times from observed survival times.
Overall, no relationship was evident between typical NIV use and survival, using either the level of NIV or
its categorised version (< 1 hour, 1–3.9 hours or 4 hours). These are demonstrated graphically for the NIV
use measured in hours (Figure 9), using the estimated/extrapolated survival for censored survival and in a
more conventional Kaplan–Meier graph for the categorisation of NIV use (Figure 10).
o
o o
o
o
o
o
o
o
o
o o
o
o
o
o
oo
o
o
o
oo
o
o
oo
o
o
o
o
o
o
o
o
o
o
o
oo
o
o
*
*
* *
*
*
*
*
o
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
0
4
8
12
16
20
24
A
ve
ra
g
e 
d
ai
ly
 N
IV
 u
se
 (
h
o
u
rs
)
3 6 12 24 48 96
Overall survival (log-scale, months)
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In the categorised version of NIV there was no association between average daily usage and overall
survival, using either the standard log-rank test (χ2(2)= 0.64; p= 0.72) or the log-rank test for trend across
the categories (χ2(1)= 0.64; p= 0.46). As shown in Table 9, the largest difference between NIV plus DPS
and NIV alone was observed in the low-use subgroup (n= 20 participants), but the interaction term
between treatment group and NIV category was not statistically significant at conventional levels in a Cox
regression model (likelihood ratio test χ2(2)= 4.14; p= 0.13).
No relationship was found when looking at the average number of hours (i.e. as a continuous measure)
and overall survival. The linear association as derived from a univariate Cox regression model showed a
small and non-statistically significant increase in survival with increasing hourly use of NIV (HR 0.98,
95% CI 0.92 to 1.04; p= 0.52). The possibility of a non-linear relationship was assessed using fractional
polynomials regression, but the best non-linear model still failed to find any association (likelihood ratio
test χ2(2)= 1.26; p= 0.53) or of any interaction between treatment and NIV use (likelihood ratio test
χ2(1)= 0.68; p= 0.41).
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FIGURE 10 Survival by NIV use: NIV use category. Censored survival times are estimated based on a censored
log-normal distribution using treatment and minimisation covariates. The line is a locally weighted scatterplot
smoother (lowess) with a bandwidth of 0.6.
TABLE 9 Overall survival by bulbar function and by NIV use
Variable
Trial arm, number of participants (deaths) Comparison
HR (95% CI) p-valueNIV plus DPS NIV
Overall survival by bulbar function
Overall test of interaction between treatment and bulbar function 0.179
Mild (9–12) 26 (21) 29 (14) 2.99 (1.49 to 6.01) 0.002
Moderate (5–8) 8 (6) 6 (3) 1.95 (0.48 to 7.92) 0.349
Severe (0–4) 3 (1) 2 (2) 0.62 (0.05 to 7.00) 0.697
Overall survival by NIV use
Overall test of interaction between treatment and NIV use 0.126
Non-use (< 1 hour daily) 9 (8) 11 (5) 3.90 (1.23 to 12.4) 0.021
Low use (1–3.9 hours daily) 9 (5) 5 (3) 1.50 (0.35 to 6.38) 0.584
Tolerant (≥ 4 hours daily) 16 (12) 18 (11) 1.63 (0.70 to 3.78) 0.253
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Non-invasive ventilation use in the first 3 and 6 months post randomisation
We also looked at whether overall survival is associated with NIV use in (1) the first 3 months post
randomisation or (2) the first 6 months post randomisation. Although this does not use the more complete
NIV data over the 12 months’ follow-up, focusing on short-/medium-term use might be seen as a
surrogate for intention-to-use NIV, as opposed to the level of use necessitated by disease progression.
Participants for whom NIV initiation was delayed are included; a participant who was initiated at 4 months
would be defined as having zero use within the 0–3 months period.
However, the findings were similar to those reported for 12-month NIV use above. Overall survival was
weakly associated with NIV use, but was not statistically significant: the HR for 3-month use was 0.96
(95% CI 0.87 to 1.05; p= 0.33) and for 6-month use was 0.98 (95% CI 0.91 to 1.07; p= 0.68).
Non-linear associations derived from fractional polynomial regression also failed to reach statistical
significance (likelihood ratio test for 3-month follow-up: χ2(2)= 2.95; p= 0.23; 6-month follow-up likelihood
ratio test χ2(1)= 0.89; p= 0.64). Again, no interaction was found between treatment group and NIV use
over either period.
Pacing use and overall survival
We assessed the relationship between pacing use and overall survival. Unlike NIV, no normative data exist
for pacing use; consequently, we did not categorise pacing usage into groups. The caveats that apply
when assessing the relationship between NIV and survival also apply here.
Figure 11 shows average pacing use against overall survival, again estimating survival times as described in
Non-invasive pacing and overall survival. As with NIV, no discernible relationship was evident. The HR for
each additional hour of use was 1.01 (95% CI 0.94 to 1.09; p= 0.707); if non-implanted patients were
excluded, the HR was 1.00 (95% CI 0.92 to 1.09; p= 0.931). Non-linear models, again derived using
fractional polynomials, did not improve the fit of the model.
Non-invasive ventilation, pacing and overall survival
The final analyses looked at the association between NIV and pacing use within the 37 participants
randomised to receive the intervention. A potential theory was that participants in the NIV plus pacing arm
may have used pacing in place of NIV. If so, this could partly explain the between-group differences, as
NIV use is known to prolong survival.
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FIGURE 11 Survival by pacing use. Censored survival times are estimated based on a censored log-normal
distribution using treatment and minimisation covariates. The line is a locally weighted scatterplot smoother
(lowess) with a bandwidth of 0.6. Circles denote actual survival times; stars are estimated times. N, not implanted.
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Nevertheless, this theory was not borne out by the data. The average use of pacing and NIV is shown in
Figure 12; the relationship between the two measures was positive rather than negative, suggesting
participants who use NIV more also tended to use pacing more. We also split the NIV plus DPS arm into
NIV-tolerant users (≥ 4 hours per day on average) and NIV-non-tolerant users (< 4 hours per day on
average), with the Kaplan–Meier curves as shown in Figure 13. Participants in the NIV plus DPS arm who
used NIV for an average ≥ 4 hours a day had a better survival than those who did not, but their survival
remained lower than the NIV alone group. Neither comparison was statistically significant at the 5%
significance level; however, the small numbers in each subgroup mean that the statistical power is low for
this comparison.
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FIGURE 12 Relationship between NIV and pacing use. N, not implanted.
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Secondary outcomes
Tracheostomy and tracheostomy-free survival
Tracheostomy-free survival is defined as the time to death or tracheostomy, whichever comes first.
One tracheostomy was reported: one participant in the NIV plus DPS arm underwent a tracheostomy
31 months after randomisation. The TFS is, therefore, very similar to overall survival, with a HR adjusted for
minimisation covariates being 2.42 (95% CI 1.28 to 4.59; p= 0.007).
Participant quality of life
European Quality of Life-5 Dimensions, three levels
The participant health utility as measured by EQ-5D-3L is shown in Figures 14 and 15. Among those
surviving to 12 months and with complete data, the difference in EQ-5D-3L scores was –0.18 (95% CI
–0.44 to 0.08; p= 0.164). However, over the follow-up period as a whole, the EQ-5D-3L score declined
quicker in the NIV plus DPS arm than in the NIV alone arm, with the longitudinal analysis providing an
average difference across time of –0.13 (95% CI –0.25 to –0.00; p= 0.042). Imputing missing data made
no material difference to the conclusions. The preplanned analysis of EQ-5D-3L scores according to NIV
tolerance and bulbar function was not undertaken because of small numbers (especially in the NIV plus
DPS arm) and the apparent deficit in overall survival.
A further analysis of EQ-5D-3L scores included both surviving and non-surviving participants, with a score
of 0 assigned to the latter from the point of death onwards. Doing so demonstrated a lower QoL both at
12 months (mean difference –0.12, 95% CI –0.24 to –0.01; p= 0.040) and also longitudinally (mean
difference –0.14, 95% CI –0.24 to –0.04; p= 0.001).
– 0.50
– 0.25
0.00
0.25
0.50
0.75
1.00
EQ
-5
D
-3
L
Baseline Month 2 Month 3 Month 6 Month 9 Month 12
DPS NIV DPS DPS DPS DPS DPSNIV NIV NIV NIV NIV
FIGURE 14 The EQ-5D-3L health utility among surviving participants over time: EQ-5D-3L health tariff.
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The findings of the EQ-5D-3L thermometer scale were consistent with those for the main EQ-5D-3L
questionnaire (Table 10). All longitudinal analyses were repeated using an unstructured correlation matrix,
as the random intercept model makes the assumption of a common correlation between repeated
measures, irrespective of their proximity in time. Although correlation decreased with time, the estimated
difference between intervention and control was virtually unaltered.
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FIGURE 15 The EQ-5D-3L health utility among surviving participants over time: patient EQ-5D-3L health tariff,
deaths imputed as zero.
TABLE 10 Quality of life
Instrument
End of follow-up analysis Longitudinal analysis
Trial arm Comparison Comparison
NIV plus
DPS (n= 37)
NIV
(n= 37)
Mean
difference
(95% CI) p-value
Mean
difference
(95% CI) p-value
Number (%) of participants alive
at 12 months
16 (43) 27 (73) – – – –
Patient QoL
EQ-5D-3L health state
(% completea)
131/178
(74)
161/209
(77)
– – – –
Complete case, mean
(standard error)
0.02
(0.09)
0.19
(0.08)
–0.18
(–0.44 to 0.08)
0.164 –0.13
(–0.25 to 0.00)
0.042
With imputation for surviving
participants, mean
(standard error)
0.02
(0.09)
0.13
(0.08)
–0.11
(–0.39 to 0.16)
0.410 –0.12
(–0.24 to 0.00)
0.056
With imputations for all
participants,b mean
(standard error)
0.01
(0.03)
0.11
(0.05)
–0.12
(–0.24 to 0.01)
0.040 –0.14
(–0.24 to 0.04)
0.001
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TABLE 10 Quality of life (continued )
Instrument
End of follow-up analysis Longitudinal analysis
Trial arm Comparison Comparison
NIV plus
DPS (n= 37)
NIV
(n= 37)
Mean
difference
(95% CI) p-value
Mean
difference
(95% CI) p-value
EQ-5D-3L thermometer scale
(% completea)
132/178
(74)
160/209
(77)
– – – –
Complete case, mean
(standard error)
34.4
(6.3)
42.3
(5.1)
3.4
(–14.5 to 21.2)
0.699 –8.3
(–17.4 to 0.8)
0.074
With imputation for surviving
participants, mean
(standard error)
36.0
(6.6)
40.0
(5.2)
1.3
(–17.6 to 20.1)
0.893 –5.6
(–14.5 to 3.2)
0.212
With imputation for all
participants,b mean
(standard error)
14.8
(3.9)
27.4
(4.8)
–13.4
(–25.9 to 0.9)
0.036 –12.0
(–20.8 to 3.1)
0.008
SF-36 aggregate physical health
score (% completea)
110/154
(72)
133/174
(76)
– – – –
Complete case, mean
(standard error)
25.4
(4.2)
21.8
(1.8)
7.4
(–1.9 to 16.8)
0.110 0.2
(–2.2 to 2.5)
0.900
With imputation, mean
(standard error)
23.8
(3.2)
20.6
(2.4)
8.7
(–1.3 to 18.7)
0.089 0.3
(–2.0 to 2.7)
0.780
SF-36 aggregate mental health
score (% completea)
110/154
(72)
133/174
(76)
– – – –
Complete case, mean
(standard error)
44.1
(3.7)
47.0
(4.2)
–7.8
(–20.5 to 4.9)
0.210 –4.1
(–8.6 to 0.3)
0.066
With imputation, mean
(standard error)
42.7
(4.2)
47.4
(3.5)
–8.6
(–22.2 to 5.1)
0.218 –3.5
(–7.9 to 0.8)
0.112
SAQLI (% completea)
110/154
(72)
132/174
(76)
– – – –
Complete case, mean
(standard error)
4.1
(0.5)
4.2
(0.3)
–0.2
(–1.3 to 1.0)
0.751 –0.3
(–0.7 to 0.1)
0.163
With imputation, mean
(standard error)
3.9
(0.4)
4.5
(0.3)
–0.6
(–1.7 to 0.6)
0.329 –0.3
(–0.7 to 0.1)
0.117
Carer QoL
EQ-5D-3L health state
(% completea)
109/178
(61)
148/209
(71)
– – – –
0.78 (0.11) 0.82
(0.06)
–0.08
(–0.38 to 0.23)
0.600 –0.08
(–0.17 to 0.01)
0.077
EQ-5D-3L thermometer scale
(% completea)
110/178
(62)
149/209
(71)
– – – –
81.3
(7.1)
71.0
(6.4)
12.1
(–13.1 to 37.2)
0.329 –0.2
(–7.4 to 7.1)
0.966
CBI (% completea) 93/154
(60)
121/174
(70)
– – – –
28.0
(3.2)
29.6
(3.2)
3.1
(–7.5 to 13.8)
0.536 1.2
(–2.7 to 5.0)
0.558
a Completeness is number of questionnaires obtained within time windows as a ratio of the number expected
(i.e. not including post death). Denominator includes all participants, although not all participants had assigned carers.
b Imputation comprised a health utility or thermometer score of 0 from the point of death onwards.
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Short Form questionnaire-36 items
As expected, overall physical health (as derived from SF-36) is considerably lower than population norms in
both groups, although mental health was comparable. No differences were evident between the two groups
over the duration of the study. As with EQ-5D-3L, the difference in aggregate mental health scores between
the groups was not statistically significant among surviving participants at 12 months (mean difference –7.8,
95% CI –20.5 to 4.9; p= 0.210), but was of borderline significance over the duration of the study (mean
difference –4.1, 95% CI –8.6 to 0.3; p= 0.066). Physical health appeared similar between groups on both
scales (Figures 16 and 17). Relaxing the assumption of a common correlation in the longitudinal analyses
made virtually no difference to the findings, with the correlation being relatively constant with time.
Sleep Apnoea Quality of life Index
Sleep apnoea appeared similar at all time points between the two groups (Figure 18).
Carer quality of life
The carer QoL is presented in Table 10 and, graphically, in Figures 19 and 20. There was little in the way
of difference between the groups.
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FIGURE 16 The SF-36 aggregate physical health component.
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FIGURE 17 The SF-36 aggregate mental health component.
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FIGURE 18 Sleep Apnoea Quality of Life Index.
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FIGURE 20 Caregiver Burden Inventory.
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
Relationship between quality of life, pacing and baseline symptoms
We have compared baseline scores with 12-month averages in EQ-5D-3L, SF-36 physical component
summary score, SF-36 mental component summary score and total SAQLI and see no relationship between
symptoms present and QoL scores. Figures 21 and 22 show these for SAQLI; similar patterns were
observed on other measures.
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FIGURE 21 Change (12 months –baseline) in SAQLI score in relation to baseline SAQLI score (Q12–Q14).
(a) NIV plus DPS; and (b) NIV.
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FIGURE 22 Change (12 months –baseline) in SAQLI score in relation to baseline ALSRFS-R sum (Q11–Q12).
(a) NIV plus DPS; and (b) NIV.
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Resource use
Resource use is shown in Table 11. As can be seen, the groups generally used similar levels of resources.
The exception was respiratory devices, specifically the cough assist device and suction. The number of
users was similar in both groups but the level at which they were used was somewhat greater in the NIV
alone group.
TABLE 11 Resource use
Variables
Trial arm
NIV plus pacing (n= 37) NIV (n= 37)
Number (%)
of patients Total days
Number (%)
of patients Total days
Admissions
Admissions following surgerya
ITU 12 (32%) 13 – –
Non-ITU 32 (86%) 86 – –
Admissions within 1 week of surgery 2 (5%) 12 – –
All other admissions 9 (24%) 67 13 (35%) 109
GP/emergency use
Number (%)
of patients Total number
Number (%)
of patients Total number
GP appointments 29 (78%) 165 30 (81%) 152
A&E attendances 17 (46%) 23 11 (30%) 14
Minor injuries unit 6 (16%) 9 3 (8%) 11
Respiratory device
Number (%)
of patients
Monthly use
(when usedb)
Number (%)
of patients
Monthly use
(when usedb)
Cough assist use 12 (32%) 4.2 10 (27%) 10.0
Breath stacking 5 (14%) 8.6 6 (16%) 6.7
Suction 7 (19%) 2.4 5 (14%) 9.5
Other resource use
Number (%)
of patients Total number
Number (%)
of patients Total number
Physiotherapy 22 (59%) 144 24 (65%) 165
Occupational therapy 22 (59%) 127 24 (65%) 99
Other 13 (35%) 57 16 (43%) 86
A&E, accident and emergency; ITU, intensive care unit.
a Denominator is all participants but only 32 were implanted, all of whom required postoperative stay.
b Monthly use defined as total reported uses/total follow-up (in months) among users.
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Safety
Adverse events
A total of 243 AEs were observed, 162 of which were in the NIV plus DPS arm. Taking into account the
differential follow-up owing to survival differences, this equates to 5.9 events per person-year in the NIV
plus pacing group, compared with 2.5 events per person-year in the control group (Table 12). Eight of the
events occurred in patients who had not been implanted.
TABLE 12 Adverse events
Category
Trial arm
NIV plus pacing NIV
Number
of AEsa
Number (%) of patients
with an event
Number
of AEs
Number (%) of patients
with an event
Any AE 162 (8) 29 (78%) 81 23 (62%)
Respiratory 45 (5) 25 (68%) 19 14 (38%)
Type of respiratory event
Chest infection 20 12 (32%) 11 7 (19%)
Respiratory failure 10 (2) 10 (27%) 5 5 (14%)
Breathless – unclassified 5 4 (11%) 3 2 (5%)
Pneumothorax/capnothorax 5 5 (14%) 0 –
Blocked airway 3 (3) 1 (3%) 0 –
Cough 1 1 (3%) 0 –
Pulmonary embolism 1 1 (3%) 0 –
Pain 23 10 (27%) 10 6 (16%)
Gastrointestinal 17 10 (27%) 12 9 (24%)
ALS symptoms 18 (3) 8 (22%) 7 3 (8%)
Insertion/removal of PEG/PIG 9 5 (14%) 10 9 (24%)
Genitourinary 7 3 (8%) 8 3 (8%)
Infection of PEG/PIG 10 3 (8%) 2 1 (3%)
Dermatological 6 3 (8%) 4 4 (11%)
Wire problems 8 5 (14%) 0 n/a
Cardiovascular system 4 4 (11%) 2 2 (5%)
Psychiatric 5 4 (11%) 0 –
NIV specific 3 3 (8%) 2 2 (5%)
Wire infection 4 3 (8%) 0 n/a
Central nervous system 1 1 (3%) 1 1 (3%)
Other 2 2 (5%) 4 3 (8%)
n/a, not applicable; PEG, percutaneous endoscopic gastrostomy; PIG, per oral image-guided gastrostomy.
a Numbers in brackets denote SAEs among the five NIV plus DPS participants who did not undergo implantation.
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Serious adverse events
Serious adverse events are presented in Table 13. Again, more SAEs were observed in the NIV plus pacing arm.
TABLE 13 Serious adverse events
Category
Trial arm
NIV plus pacing NIV
Number
of SAEsa
Number (%) of patients
with an event
Number
of SAEs
Number (%) of patients
with an event
Any SAE 46 (5) 27 (73) 31 19 (51)
Respiratory 29 (5) 21 (57) 13 11 (30)
Type of respiratory event
Chest infection 10 9 (24) 6 5 (14)
Respiratory failure 10 (2) 10 (27) 5 5 (14)
Breathless – unclassified 2 2 (5) 2 1 (3)
Pneumothorax/capnothorax 3 3 (8) 0 –
Blocked airway 3 (3) 1 (3) 0 –
Pulmonary embolism 1 1 (3) 0 –
Insertion/removal of PEG/PIG 6 4 (11) 9 8 (22)
Gastrointestinal 3 3 (8) 2 2 (5)
Cardiovascular system 3 3 (8) 1 1 (3)
Pain 1 1 (3) 3 2 (5)
Wire problems 2 2 (5) 0 n/a
ALS symptoms 1 1 (3) 0 –
Dermatological 0 – 1 1 (3)
Genitourinary 0 – 1 1 (3)
Other 1 1 (3) 1 1 (3)
n/a, not applicable; PEG, percutaneous endoscopic gastrostomy; PIG, per oral image-guided gastrostomy.
a Numbers in brackets denote SAEs among the five NIV plus DPS participants who did not undergo implantation.
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Adverse events related to surgery or pacing
In total, 31 events (in 15 different participants) were adjudged to have had an AE with either a ‘definite’
or a ‘probable’ relationship to pacing. These AEs are listed in Box 1 and Table 14. Seven surgical
complications or device-related adverse events were recorded on the date of procedure.
Cause of death
The causes of death are presented in Table 15. Although participants in the NIV plus pacing arm had
shortened overall survival, mortality was not obviously attributable to the procedure or to the pacing.
One participant in the NIV plus DPS arm died 45 days after surgery; none of the remaining participants
died within 3 months of the procedure.
BOX 1 Adverse events related to surgery or pacing
Surgical complications or device-related adverse events on the date of procedure
Bilateral pneumothorax.
Capno/pneumothorax.
Tension pneumothorax.
Right-sided pneumothorax requiring chest drain.
Lines 1-+ 2-captured electrocardiogram trace. Maximum settings established.
Small nick to spleen which caused bleeding. Pressure was applied and bleeding stopped after 5 minutes.
Abdominal pain.
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TABLE 14 Adverse events related to pacing
Event
Frequency
(if > 1)
Respiratory events related to pacing (n = 5)
Bilateral pneumothoraxa (D)
Tension pneumothoraxa (D)
Right-sided pneumothorax requiring chest draina (D)
Capno/pneumothorax (D)
Difficulty with breathing (P)
Wire infections (n = 4)
Infection to electrode site (D) 4
Wire problems (n = 4)
Anode wire pulled/fell outa (D) 4 (2 SAE)
Anode replaced as the anode was causing the abdominal pain (D)
Diaphragmatic pacing wire number 1 showing X on pacer. This will need replacing (D)
Patient feels his skin is being burnt by anode bypass (P)
Sore pacing wire insertion site (D)
Pain (n = 12)
Anode replaced as the anode was causing the abdomen pain (D)
Pain in back and shoulders (P)
Pain in ribs (P)
Shoulder pain (on contraction) (P)
Shoulder pain on pacing (D)
Pain to left side of chest on pacing (D)
Discomfort during pacing (D)
Back and shoulder pain post operation (D)
Pain – abdominal (D)
Pain in left shoulder and stomach when pacer switched on (D)
Intermittent shoulder pain on pacing (D)
Right and left shoulder pain on pacing (D)
Dermatological (n = 1)
Bypass pad causing contact dermatitis (D)
Gastrointestinal (n = 1)
Acute gastric dilatation responded well to decompression with nasogastric tube. Well described following
upper gastrointestinal surgery although rare – was slightly higher risk because of bleeding from spleen
during surgerya (P)
a SAE.
Note
Relationship is (D)= definite or (P)= probable.
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Physiological measurements
In the light of the early stopping, the TSC requested additional respiratory function data to be collected to
augment that which was already collected at baseline (and for DP, immediately pre surgery). Specifically,
we wished to assess (1) whether or not the groups were comparable at baseline; (2) whether or not
decline appeared more pronounced in the post-surgery period among the NIV plus DPS group than in the
NIV group; and (3) the trajectory across time, in general, to see if it offered any other clues by which to
explain the findings. We were able to obtain data for patients at some of the sites for FVC, arterial carbon
dioxide and ALSFRS-R.
The purpose of the analysis was not to assess efficacy but to investigate possible treatment harm and,
consequently, we analysed the group based on actual exposure (i.e. implanted with the pacing device) as
opposed to the more conventional intention-to-treat analyses. Measurements taken more than 45 days
prior to randomisation or > 1 month after the end of scheduled follow-up were excluded. A generalised
least squares regression model was fitted in which the treatment received, time since randomisation and
their interaction were the covariates. No attempt was made to impute missing data.
The figures show some evidence that FVC did indeed decline faster in participants who were implanted
than those who were not, with the average rate of decline per month being 2.1% steeper among
implanted participants than in those without implantation (95% CI –3.4% to –0.8%; p= 0.001). It is not
easy to distinguish whether or not the decline is more pronounced in the postoperative period than the
preoperative period (and, hence, directly attributable to operation), as the latter is a short period of time.
(Figures 23 and 24).
The trajectory for PaCO2 is shown in Figures 25 and 26. In contrast to FVC, the change in PaCO2 is more
modest, with no obvious change in levels in either group.
Finally the trajectory is shown for ALSFRS-R, a measure of ALS symptomology based on a 12-item
questionnaire and ranging from 0 points (most severe) to 48 points (least severe). There was substantial
decline in the control group (on average 1.1 point per month), but the rate of decline was greater still
among participants who underwent implantation (mean difference 0.4 points per month, 95% CI –0.7 to
0.0 points per month; p= 0.035) (Figures 27 and 28).
TABLE 15 Cause of death
Cause of death
Trial arm
NIV plus DPS (n= 37) NIV (n= 37)
Total deaths 28 19
Causes of death
Respiratory failure 16 13
Chest infection 5 2
ALS 6 4
Hypothermia 1 0
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FIGURE 23 Forced vital capacity against time for implanted participants. The triangle denotes date of procedure
and the cross denotes date of death. (continued )
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FIGURE 23 Forced vital capacity against time for implanted participants. The triangle denotes date of procedure
and the cross denotes date of death.
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FIGURE 24 Forced vital capacity against time for non-implanted participants. The cross denotes date
of death. (continued )
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FIGURE 24 Forced vital capacity against time for non-implanted participants. The cross denotes date
of death. (continued )
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FIGURE 25 The PaCO2 against time for implanted participants. The triangle denotes date of procedure, the cross
denotes date of death.
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FIGURE 26 The PaCO2 against time for non-implanted participants. The cross denotes date of death. (continued )
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FIGURE 26 The PaCO2 against time for non-implanted participants. The cross denotes date of death.
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FIGURE 27 The ALSRFS-R score against time for implanted participants. The triangle denotes date of procedure and
the cross denotes date of death. (continued )
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FIGURE 27 The ALSRFS-R score against time for implanted participants. The triangle denotes date of procedure and
the cross denotes date of death.
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FIGURE 28 The ALSRFS-R score against time for non-implanted participants. The cross denotes date
of death. (continued )
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FIGURE 28 The ALSRFS-R score against time for non-implanted participants. The cross denotes date
of death. (continued )
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Chapter 5 Qualitative substudy
A qualitative longitudinal study formed a subelement of the trial design. This was an essential part ofthe DiPALS trial, as it is important not only to investigate the efficacy of DP but also to ensure that any
extension of life was not to the detriment of QoL. The qualitative substudy therefore was designed to
complement the data collected via the SF-36 and SAQLI by providing additional depth of insight into
patient and carer perceptions and experiences of the DPS intervention.
The aim of the qualitative component was to evaluate the acceptability and perceived impact of the
intervention on patients with ALS and their family.
Outcomes
The primary end point was the perceptions of patients and carers regarding acceptability and impact of
the device.
Qualitative substudy methods
Sampling
We purposively selected participants for the qualitative element of the study from those randomised to the
pacing intervention arm of the trial. We intended that our sample would include diversity in terms of
patient sex, age, ALS type, and across the different ALS centres taking part in the trial.
Potential participants for the qualitative substudy were identified following randomisation. They were
approached by study leads at the research centres at the first follow-up appointment after surgery.
The qualitative study component was outlined to potential participants, and an information sheet related
to this component was also provided (see Appendices 7 and 8). If they were willing to take part, contact
details were provided to a qualitative researcher who was independent of the main trial team.
It was expected that ALS patients would not be able to tolerate an interview in addition to other trial
assessments when they attended follow-up visits at local sites. Therefore, an experienced research fellow
(SB) conducted semistructured interviews at a time and location that was convenient for participants.
Data collection
Qualitative interviews with patients and carers were carried out at two time points: 1 month following
initiation of the pacing intervention and, when possible, 6 months later. Interviews were conducted
in patients’ homes lasting 45–60 minutes and were based around a predefined interview schedule
(see Appendix 18).
Prior to the interview taking place the researcher checked the contents of the patient information sheet
with participants, answered any questions, and a consent form was signed. Participating carers were
interviewed together with patients or separately, as preferred by respondents. During the interviews a total
communication approach was used for participants with impaired speech, whereby use of gesture, writing,
communication aids and forced alternative responses were used to facilitate responses.
Interviews were audio-recorded. The first interview was carried out 1 month following implantation, and
focused on expectations and experiences of the surgery, learning to operate the system, and perceptions
regarding any impact on life. The second interview, undertaken when possible approximately 6 months
post implantation, was considered an appropriate time to allow patients using DPS (and caregivers) to
become familiar with the intervention and to have gained an understanding of potential impacts.
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Therefore, the second interview explored experiences of the system, views regarding DP versus NIV,
perceptions of any effects, and reflections in hindsight on taking part in the trial.
Data analysis methods
Interviews were transcribed verbatim and transcript data were analysed using techniques of thematic
analysis, where similar concepts or ideas across the interviews are brought together and assigned a code.
Relationships between codes are then examined to develop a network of themes and subthemes recurring
across the data. Systematic coding and retrieval of data was supported by the ATLAS.ti software (version 7,
ATLAS.ti Scientific Software Development GmbH, Berlin, Germany). Data were shared and discussed at
several qualitative team meetings to establish consensus for the coding network.
Participant characteristics
Fourteen patients and eight carers took part in the qualitative substudy. Eight patients were male and six
were female; 10 were aged in their sixties, and four were aged in their fifties. On the ALS FRS-R at entry
into the study, 11 patients were in the mild impairment range for bulbar function and three were in
the moderate bulbar impairment range. In terms of limb function, one patient scored > 9, 12 scored
5–8 (moderate impairment), and one scored < 5. Patients were under the care of five different ALS
centres. Nine participants were interviewed at both time points, two patients had died in the interval
period and two patients preferred not to be followed up because of disease progression. One further
person was not using the system at initial visit, or subsequently, and declined follow-up.
Usage of the diaphragm pacing system
At first visit, all but one of the participants had the DPS in use (although one system had technical issues
with a broken wire and had not been used for a few days). Ten participants were using DPS during the
daytime. Two preferred to use it overnight, and another used it during both day and night. Nine patients
had it in operation for 1.5–2 hours per day (in a number of half-hour sessions), with one person reporting
5 hours, and three people estimating at least 6–8 hours’ daily use. Seven patients were also using NIV
overnight, and one used NIV in the daytime for short periods. Five participants were struggling to use,
or were unable to use, NIV, and one person was awaiting initiation on NIV.
At the 6-month follow-up, use of DPS among this sample of participants during the daytime ranged from
20–24 hours (two patients) to 2–5 hours (five patients). Five patients used NIV overnight, two used it for
20–24 hours; two participants used it for 7–9 hours overnight, one occasionally and another rarely.
Results
Patient and carer experiences
Participants described the process from initial approach to be involved in the study, to ongoing usage of
the pacer and perceived outcomes. The recurring themes and subthemes are presented in Figure 29.
Owing to the extensive volume of material we focus on the themes most frequently found and include a
number of verbatim quotes to illustrate key points.
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The surgery
Experiences of the surgery
The prospect of surgery (in particular having a general anaesthetic) was described as a concern for some:
I was more concerned about being put to sleep rather than the surgery.
I was a bit concerned about having the op, yeah; any operation you have, as an ALS patient there is
going to be some side effect.
There was obviously the consideration I might not go under and come out properly.
He did have a few worries about it.
She’s bad, she always has been with gas.
Whereas other patients reported little apprehension:
I would say the operation seems quite straightforward.
As far as I’m concerned it’s just a minor operation.
Recovery
Several patients mentioned their expectation that they would stay in hospital only overnight following the
surgery. All but two, however, had stayed longer:
Coming home it took about four days I think.
It might’ve been a week and a day.
A day, two days . . . but it turned out to be longer than that.
There were reports of postoperative pain for around half of patients:
My right shoulder, when I came out from anaesthetic, you know, that was killing. I couldn’t move.
I got pain in my shoulders, which they said was referred pain.
He did have painkillers in the first few days, he did have a lot of . . . I think there was quite a bit of pain.
I had a lot of pain, yeah; had this terrible pain on this side.
The surgery
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FIGURE 29 The patient journey trialling DP.
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Impact of surgery
Four participants mentioned that the surgery had impacted adversely on their ALS symptoms:
It took him a while to seem to pick up after it, which I didn’t expect.
It wasn’t bad; the only thing it did do . . . sent my ALS out of kilter.
Since coming out of hospital I’ve definitely felt weaker.
If you have any kind of procedure you are going to take a few steps backwards and you’re going to
have to recover again.
Operating the equipment
Expectations versus reality
Participants described their reaction on first seeing the system. All had seen either the equipment or
pictures of it at their consultation prior to agreeing to take part and, for most, expectations were not
different from reality:
It was what I expected really; I just expected what I’d got.
However, some patients described how they had struggled to visualise exactly what it would look like:
They kept saying well it’s like a pacemaker . . . and we didn’t know really to be honest.
I mean when you wake up and see it on you, it’s a bit of a shock.
I didn’t know what I was expecting.
A lot more (incisions) than what I expected . . . they’d said keyhole I think I just got an idea of a cut
here and a cut here.
I don’t know what to expect, basically; I wasn’t sure what it would, cos even looking at a picture
you’re not sure what it’s going to look like on you.
The main area of surprise seemed to be regarding the narrow width of the wires:
You kind of think oh wires out your tummy you just expect something that you plug into a computer.
And the wires, cos they’re more like threads . . . you always think wires are thicker don’t you.
There were no instances of patients expressing concerns regarding having technology within and, attached
to, their bodies. This perhaps is to be expected from individuals who had agreed to take part in the trial.
Participants, although recognising it could be a little strange, mostly seemed to have taken having the
system fitted in their stride:
Really weird to have a plug into you; it’s a bit science fiction really.
I’ve got all these bits of wires in me now.
They’re (family) fascinated with it, I’m actually quite OK with it.
It’s not the nicest thing hanging from your diaphragm but . . .
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I said yeah, you know, no problem; something to get your head around.
There is something there still physically on your, attached to you.
He (patient) loves the technology.
Ease of operation
There was consensus among participants that the system was easy and trouble-free to operate:
It was a piece of cake, no problems.
It’s easy to manage, there’s nothing to do other than make sure the cable’s connected properly.
It’s so easy to manage; it is a very simple device to use.
That’s easy, yeah, just press two buttons, even I can do that.
It’s really simple.
A small number of patients with severe limb impairment needed assistance to switch the device on
and off.
Plugging and unplugging
Plugging the external lead on to the receiver on the body was described as being potentially awkward:
The actual fitting of the pacer on to this is very awkward for somebody with ALS. It’s very small and
it’s very hard to get in exactly the right place.
You put it in, it doesn’t click, so you keep trying, trying, trying, you know, so it is a bit
annoying actually.
She had a job trying to fit it because it was the other way round, it took her some time.
Sometimes it goes in really easily.
It is a bit of a struggle to get it in.
The difficulty in attaching the lead to the connector was described as being made more challenging owing
to the siting of the connector:
If it were a little bit lower down maybe they could do it themselves.
Because where it is it’s quite hard to see, especially for a lady.
If it were a bit lower down it’d just go in.
You can’t see a thing cos it’s under my bust.
I think the location of the wire is such a way that I can’t even look at it properly.
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
Sensation of the pacer working
Patient reports of the sensation of the pacer working varied considerably. The majority of participants
described it as a noticeable, but not painful, feeling:
If I’m watching something, if I’m talking to somebody, you forget about it.
It’s hard to describe; it’s quite strong and almost like beats.
It’s a bit like a needle scratching down your stomach.
It’s like really, really strong butterflies.
It just like your heart ticking away, you know it’s there but you don’t know it.
Just a little electric pulse.
Like a flutter, fluttering feeling.
It’s not painful; within a day you don’t really notice it.
I would not say it’s pleasant, I mean it is definitely unpleasant, but it is not unbearable.
You do feel something but it’s not uncomfortable; he initially used to say ouch, but now he’s stopped
doing that.
Others, in contrast, experienced higher levels of discomfort:
It’s like getting shocked with an electric fence.
it affects the left shoulder; it is a bit painful when you inhale.
The most excruciating pain she’s ever experienced in her life, no exaggeration.
Because of the discomfort and pain that he’s had, he hasn’t been using it as he should be.
It can be very uncomfortable; this is very painful.
For three participants, the level of pain experienced limited the length of time that they were able to use
the system. At follow-up interview, these individuals had continued to attempt to use the pacer despite
their discomfort. One person had found that if it was much more tolerable when lying down at night .
Impact on life
The system was not reported to have an adverse impact on life (apart from those experiencing
significant pain):
My life just goes on normally, I work around it.
No it doesn’t have any effect; I can just sit and have it on.
We just fit it round our routine.
You just sit back and watch something else and do something and suddenly half an hour is gone.
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Only one patient highlighted that making time for several interventions impacted on their day:
It has now structured our whole day . . . cos we can’t do this at night with three hours on that,
two hours on this, feeds. The entire day is structured out by these things now.
Another patient reported that the system set off security alarms in shops, so this affected where
they went.
Portability
Several participants mentioned that they had been surprised at the size of the external battery unit, and
some that they struggled to put it in a clothing pocket:
It was bigger than I was expecting; well I’d seen it on my [tablet] but of course on there it looks
quite small.
It is a little bit on big side, for what’s in it; I would think they could have made that like half size
of that.
I wouldn’t like it in my pocket; it might come out.
A bit big even for our pockets.
I’m not sure where box is going to go.
It needs a bag provided, you know.
It needs either a waist strap or a shoulder strap or just something to carry it around in.
The solution that most adopted was to use a waist bag or ‘bum bag’:
We just altered a bum bag, didn’t we, to use.
I’d certainly say well try a bum bag.
My wife thought of that, because it was getting a bit awkward, what do you do with this thing and
this box, so she said OK, we can use this bag so we took it out and then she put, put a hole in
the side.
Fragility of the system
The system was perceived to require careful handling, with worries regarding pulling or catching and then
breaking the external wires and connector, or dropping the external unit. Patients were anxious that if the
wires broke that they would need to undergo further surgery, and that if they pulled on the wires that
the internal mechanism would be damaged:
Those wires so minute you know you could look at them and they break.
I’ll have to make it really secure so I can’t catch it and pull it.
Because I’m liable to drop it, the flex might just drop and I don’t want it to pull on it.
Well I don’t know how strong the wires are, are they strong enough, I mean if I pull it will it
come out.
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You’re careful with it, cos obviously it’s quite delicate.
It could slip off, you could knock it.
I think the only thing that is a concern is just if you pulled on the wires.
But if ever I pull it it’s like pulling wires out of your flesh isn’t it really.
The wires could catch on clothing or catch in fingers:
You can catch it quite easily; when you bend over they catch.
I have to be a bit careful I caught it my pyjamas over the thread the other day.
Night-time was a particular concern in terms of pulling the wires:
She was worried if she turned over and pulled it.
I’m a bit worried about sleeping with it cos I turn quite a bit at night.
These worries were not unfounded, with two patients in the sample having to suspend use of the pacer
shortly after initiation because of broken wires:
One of the wires is broken.
The reason the wire came out was I was sitting on the bed and the phone rang and I had on it and
I forgot so it went to the floor.
Washing and showering
There was variation in level of patient and carer concern regarding getting the system wet. For most
individuals, showering with the connectors exposed was not of concern after the incisions had healed:
Not too worried because the wires have to be kind of watered because it’s in your body and there’s
fluids there all the time.
I don’t think about it.
She’s been in the bath of couple of times it’s no bother.
It’s fine now; I just shower like you would normally.
Three participants were more cautious and, at follow-up interview, had continued to ensure that the
connector was kept dry:
They say there’s no problem if you wet it but he knows that electricity and water don’t mix.
Even now I put a piece of plastic on it.
Some people say don’t get it wet, other people say it doesn’t matter; my advice was just cover it when
you shower.
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Perceived outcomes
Perceived effect
At first interview, 4 of the 14 patients reported that they had noticed some improvement to their
breathing or had a stronger voice, changes that they attributed to using the pacer. Of the nine who could
be followed up, two perceived that the pacer had been of benefit to their breathing. The most frequent
responses to questions regarding any perceived benefit were uncertainty, and hope that benefit may be in
the longer term:
There’s very little I can attribute to this.
I can’t actually tell if it’s helping me to breathe easier or not.
I don’t know.
You don’t know if it’s working or not.
Hopefully the diaphragm will benefit from that exercise and stand me in good stead later on in life
that’s the only way I’m looking at it.
The progressive nature of the disease meant that it was challenging for patients and carers to ascertain
where a patient would have been if they had not trialled the pacing:
I don’t know how to tell if the having pacer has and will make a difference.
We don’t know how quickly deterioration would be anyway.
He hasn’t seemed to have improved any but then again he could have been worse than this if he’d
not had the machine on so it’s really hard to compare isn’t it.
I don’t know whether it’s because of diaphragmatic pacing or whether they think that it would be
the same.
It’s hard to tell because we, we feel he’s deteriorated quickly anyway.
Preference for pacing versus non-invasive ventilation
Although there was very limited evidence of perceived benefit, patients generally reported that the pacer
was preferable to NIV:
I much prefer this [pacer], I have a problem with the other one [NIV].
If that works is it possible I won’t have to have the NIV.
If they could just replace the mask with that.
Definitely the pacer, because the pacer that is brilliant, the mask is a nightmare.
If I had a choice it’d be this one [points to pacer].
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
There was a recognition, however, that benefits were more easily attributable to using NIV:
I can’t say that if I’m battling to breathe and I put this thing (pacer) on I get instant relief whereas if
I put the NIV on, the minute I put it on I can feel it taking over.
I don’t have enough confidence in this [pacer] to tell me it’s replacing that [NIV].
I think I’d go for the pacer rather than the mask but I feel that the mask does more good.
I’d have the breathing mask because it makes me sleep and I feel better in the morning cos I’ve had a
good night’s sleep but I’d pick the pacer if it did the same thing as the breathing mask.
Some patients emphasised that the two interventions were operating differently:
When you get up in the morning you can feel fresh in a way, this is a completely different device
which agitates your diaphragm.
To be perfectly honest, with this disease I think you need what you need; they’re not doing the same
thing; there’s good things and bad things about both.
Reflections in hindsight
Participants were asked what they would say to another patient with ALS who was considering having the
pacing system, and their reflections on taking part in the study. None of the patients at the first interview
reported that they regretted having the pacer fitted:
So far we have no regrets.
If you’ve got a chance of it go for it.
With this disease, there are so few things that anybody can do for you that, to be perfectly honest,
if you get chance or something then I’d grab it with open arms.
Well I’d say go for it, you’ve got nothing to lose.
At second interview these views were unchanged:
Well tell ‘em to have it, I mean everything that helps to keeping your breathing is obviously good,
the only thing is you don’t know if it is helping you or not.
They should go for it.
You don’t have any regrets do you . . . absolutely none; like everything it’s got to be an individual
decision because with ALS whatever you do you know that there’s a finite about what you can do but
in this instance I would say have a go.
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Chapter 6 Discussion
Main findings
The main finding was that DP had a deleterious effect on overall survival. In the DP plus NIV arm compared
with the NIV alone arm, the observed reduction in overall survival was 11.5 months and the reduction in
survival from symptom onset was 17 months.
The impact on QoL was at best minimal, with no statistically significant differences observed between the
arms in patient or carer preplanned QoL measures SF-36, EQ-5D, SAQLI and CBI. The lack of benefit on
the SAQLI is particularly noteworthy, as the one RCT of NIV demonstrated improved QoL and respiratory
symptoms using this inventory.1 A planned cost–utility analysis did not go ahead following the lack of
efficacy. However, we analysed the EQ-5D-3L scores, as this is a valid QoL tool in its own right. The patient
health utility (EQ-5D-3L) was slightly lower in the NIV plus pacing group than in the NIV alone group,
especially when a score of 0 was imputed to EQ-5D-3L following death. Differences were modest at any
individual time point, but longitudinal analysis demonstrated statistically and clinically significant differences
on all patient EQ-5D-3L questionnaires, indicating that at least on one measure, the addition of DP, was
associated with a reduction the QoL of patients.
There were more AEs in the NIV plus DPS arm, and many of these were related to the surgery, for example
postoperative pain. The type and frequency of the AEs are consistent with those published for ALS,
and device-related AEs (e.g. discomfort on pacing or wire failure) were less common than observed in
the SSPB, as submitted to the FDA.11 There are three immediate plausible explanations for the latter
finding: (1) improvements in using the device with time, (2) patient under-reporting or (3) the fact that
AEs were reported over a longer follow-up (in our study, AEs were reported up to death or 1 year post
randomisation, whichever came first). Nevertheless, the low rate of pacing-related AEs support our
assertion that the implantation procedures and management of the NeuRX RA/4 DPS was conducted
in accordance with previous reports and the manufacturer’s recommendations.
More deaths were observed in the NIV plus pacing arm; however, the causes of death were similar across
the arms and consistent with expected causes of death in ALS. This observation suggests that the NeuRX
RA/4 DPS is not modifying the disease phenotype of ALS leading to death through some unusual
mechanism. The causes of death would support the hypothesis that the disease course is accelerated by
the intervention. It is perhaps important to emphasise that postoperative mortality was not encountered,
with only one participant death within 3 months of implantation (and this was 45 days after the
procedure). This rules out the direct effects of the implantation procedure itself as the cause of the
observed harm in the NIV plus pacing arm.
A full health economic analysis of the cost-effectiveness of the NeuRX RA/4 DPS was planned. Given the
lack of efficacy and apparent harm, this analysis did not go ahead. We have, however, compared the
health-care resource use between the two arms. This is helpful in exploring if there were differences in
other treatments or resources that could have impacted on the results. We found no difference in the way
participants accessed health care. Similarly, access to other respiratory interventions, such as cough assist,
breath stacking and suction, was comparable. There was a tendency for patients in the NIV arm to use
cough assist and suction more frequently, whereas those in the NIV plus pacing arm used breath stacking
more. The impact of these differences cannot be quantified, but they are unlikely to explain the differences
in survival we observe.
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Survival in relation to non-invasive ventilation and diaphragm
pacing use and compliance
One concern was that perhaps patients in the NIV plus pacing arm would reduce NIV use in favour of DP
use. If this occurred, then the negative impact of not using NIV, a proven intervention to prolong life, may
have caused the survival difference between arms. Somewhat paradoxically, NIV use was similar in both
arms, and, when modelled, NIV use did not influence survival, although this is likely to reflect increasing
use of ventilation as prognosis deteriorates. We explored whether or not bulbar function at the time of
randomisation and whether or not NIV tolerance influenced survival. In the RCT,1 NIV individuals with poor
bulbar function did not experience the survival benefits that those with good bulbar function obtained.
Bulbar dysfunction is one obstacle to successful NIV use, but there are others, and indeed, some patients
with significant bulbar dysfunction can manage NIV. Therefore, looking at NIV tolerance is likely to be
the most informative. The impact of bulbar function at the time of randomisation was negligible among
the subgroup of patients who were intolerant of NIV and had a trend towards worse survival in the NIV
plus pacing arm than in the NIV arm. Although the numbers are small, this would suggest that DP should
not be considered an alternative in patients not able to tolerate NIV. This is particularly disappointing, as
despite all efforts there is a consistent 20% or so of individuals with ALS who cannot get on with NIV and
would benefit from an alternative means of respiratory support.2,3
Diaphragm pacing was well tolerated, with the majority of patients reaching the set targets for pacing.
We explored whether or not the amount of DP use influenced survival and did not find an association.
One might have expected, given the overall findings, that the more an individual used DP, the worse the
outcome would be. We did not observe such a dosing effect. The study was not designed to look for a
dosing effect and one needs to be cautious in interpreting observational data. However, this observation
would lend soft support to the hypothesis that the indirect effects of surgery itself may have been the
major contributor to the harm.
Qualitative study
The inclusion of qualitative data relating to patient and carer experiences involved in trials is important, as
it ensures that research does not focus only on intervention effectiveness, but also considers elements of
implementation and acceptability to participants. The use of a qualitative substudy is a significant strength
of this trial, as it provides a comprehensive analysis and interpretation of patient perspectives.
The qualitative data provide valuable insights into the views and experiences of patients and carers
following their decision to take part in the trial of DP. For most participants there were few factors
adversely impacting on their use of the intervention, although some patients in contrast described severe
pain or discomfort.
The qualitative data confirm previous reports of pain experienced by some users of DP and highlight the
wide variation in experiences: a longer than expected hospital stay; the perception among some that the
surgery had negatively impacted on their functioning; the perceived ease of operation; issues of portability;
and concern regarding fragility of the device.
In general, the participants found the device to be acceptable in terms of ease of operation and limited
impact on QoL. The majority of users described hoped-for rather than perceived benefit. Although the
majority of participants were uncertain regarding any benefit obtained, none appeared to regret their
decision to trial the device. They described the limited options available to people with ALS and
their willingness to try any available interventions.
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Although the data offer important insights into patient and carer views and experiences of DP, the
qualitative data may be limited by the small sample size and by the fact that these participants had been
invited and agreed to participate in a clinical trial. We were successful in achieving a sample relatively
balanced by participant sex; however, other differences between our qualitative substudy sample and
wider groups of patients with motor neurone disease may need consideration.
Understanding the results
There has been a presumption that DP offers probable benefit; however, the mechanism by which such
benefit is conferred is unclear and unproven. One potential mechanism put forward is that DP reverses an
effect on the diaphragm muscle fibres whereby a shift from a predominance of efficient type I fibres to
inefficient type IIb fibres occurs.12 This hypothesis is extrapolated from observations in a population
receiving closed-system invasive ventilation support and it is not known whether or not NIV has a similar
effect on the diaphragm muscle fibres.28 A further hypothesis is that DP leads to conditioning of the
diaphragm muscle (i.e. increase in muscle mass). There are a few case reports of this, although the
functional consequence of this is unknown should it occur.29 Improved compliance of the lungs and
prevention of basal collapse; restoration of the co-ordination of breathing, lost as a result of upper motor
neurone dysfunction; and increased tidal volumes are other potential as yet unproven mechanisms.
Unhelpfully, we can be no more certain as to why DP may be harmful. The possibilities are a direct effect
of pacing (i.e. electrical stimulation) on either the muscle or the phrenic motor neurones. The physiological
effects of pacing have not been studied in humans. In canines and rodents, it is clear that neuromuscular
damage can be induced depending on the parameters of pacing and that the effects observed differ
between healthy and disease models.8,9 A simpler explanation may be that pacing causes excessive muscle
fatigue or that asynchrony between pacing induced diaphragm contraction, patient- and/or NIV-triggered
breaths is an issue.
Undertaking surgery in patients with ALS and respiratory failure does present some challenges and angst
among health-care professionals. Our study confirmed the finding of others that general anaesthesia can
be undertaken safely in terms of perioperative mortality, with no deaths within 30 days of the implantation
procedure and only one within the first 3 postoperative months.7 However, there is evidence that the
consequences of surgery and general anaesthesia may be less immediate and not apparent initially.
A retrospective review of ALS patients undergoing surgery for any reason demonstrated an apparent
acceleration of ALS disease progression post surgery, suggesting a potential disease-modifying effect,
albeit one that is not well understood.10 Direct effects of anaesthetic agents and surgical stress, with the
release of systemic pro-inflammatory cytokines, are postulated to contribute to the observed effect. It is
possible that such indirect effects of surgery are contributing to the survival differences in the DiPALS trial;
however, this is far from certain. In an attempt to minimise patient burden and focus on survival and
cost-effectiveness, during the grant peer-review process secondary outcome measures detailing
progression of ALS (ALSFRS-R score) and respiratory function (FVC) were removed from the protocol. When
the negative outcome was identified, the TSC requested that an attempt was made to retrospectively
collect any functional data on participants during the follow-up period. Clearly, this is an unplanned and
retrospective analysis on incomplete data and conclusions based on this analysis need to be cautious. The
baseline data at randomisation demonstrate the two arms to be balanced in terms of respiratory function
and ALSFRS-R score. However, it does appear that there was a change in the rate of decline of FVC and
ALSFRS-R score following implantation. This finding, however, would be consistent with either an indirect
effect of surgery or a direct effect of pacing, as described in the Discussion.
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The results of the Diaphragm Pacing in patients with
Amyotrophic Lateral Sclerosis trial in context
Our findings are at odds with the FDA summary of SSPB, which reported a survival advantage for DP of
16.1 months from symptom onset and 9 months from the point of NIV initiation, compared with NIV
alone, in a historical cohort.11,30 This compares with our findings of a reduction in survival in the NIV plus
DPS group by 17 months from symptom onset and 11.8 months from randomisation. The median survival
from symptom onset in DiPALS was 45 months in the NIV arm, 28 months in the NIV plus pacing arm and
56 months in the SSPB pacing study.
This raises several possibilities, which include that there are differences between the populations in
the DiPALS trial and in previous cohort studies; the DP intervention has been delivered differently; or other
treatments that impact on survival are different between the DiPALS trial and previous studies. We will
discuss these three possibilities next.
The Diaphragm Pacing in patients with Amyotrophic Lateral
Sclerosis trial population compared with other studies of
diaphragm pacing
The population in the DiPALS trial other than having a male preponderance is relatively typical of an ALS
population with age, proportion of limb to bulbar onset, rate of decline of ALSFRS-R score, all as would
be expected.31 The complete data set, including baseline study population characteristics, from the
uncontrolled multicentre cohort study which led to FDA approval on humanitarian grounds of the NeuRX
RA/4 DPS (HDE), has to date not yet been published. Therefore, it is not possible to compare the
populations and, therefore, it is challenging to fully understand the differences in the reported outcomes.
The broad inclusion criteria for the pilot and pivotal phases of the cohort study were evidence of residual
bilateral phrenic nerve function and a FVC of < 85% at screening and > 45% at DPS implantation, but
specific details, such as the mean age, FVC and bulbar function of the recruited population, are not
publicly available.11 The FVC inclusion is higher than the 75% used in the DiPALS trial and if a significant
number of patients lay in the 75–85% range for FVC, then this would contribute to some of the difference
observed. More immediately, however, it is noteworthy that of the 144 patients enrolled only 106 were
implanted and 84 included in the analysis of overall survival. The reasons for these exclusions are not
provided, but we speculate that these may, again in part, explain the disparity. The cohort study contained
a lead-in phase of 3 months before implantation during which time patients were monitored. The details
of 38 patients who did not undergo implantation are not reported. It seems likely that some have been
excluded because they rapidly deteriorated, but this is not clear and there may have been other criteria
used. Of the 106 implanted, the data of only 84 patients contribute to the SSPB report, two patients
having been lost to follow-up and 20 not meeting the HUD criteria. This cohort is therefore a highly
selected group and may not be generalisable to the wider ALS population. In contrast, our trial used an
intention-to-treat approach in which all consenting participants were analysed, including patients who
subsequently declined rapidly in either group. Therefore, we suspect baseline difference in the study
populations may be a major cause of observed survival differences.
Outside ALS, DP is licensed for patients with spinal cord injury in several territories including the USA and
Europe. As with ALS, the marketing licence was granted on humanitarian grounds and on the basis of a
small (n= 50) cohort study of patients with spinal cord injury resulting in a poorly controlled diaphragm and
requiring continuous mechanical ventilation.11,30 Forty-eight of the 50 had achieved a successful outcome,
defined as a continuous period of at least 4 hours without the assistance of a mechanical ventilator; one
participant was unable to achieve diaphragmatic pacing. The average follow-up was 1.4 years, during
which four deaths were reported, none of which was considered to be related to the device.11 Thus, as with
the ALS cohort data, there is limited evidence to support or refute the safety of DP.
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Delivery of diaphragm pacing in the Diaphragm Pacing in
patients with Amyotrophic Lateral Sclerosis trial compared
with other studies
The device manufacturer (Synapse Biomedical) provided training for surgeons and site staff in all aspects of
the intervention, as is standard practice when it supplies the NeuRX RA/4 DPS within a service. For example,
an experienced surgeon from Synapse Biomedical attended the implantation procedure and proctored the
local site surgeon until he or she was competent to insert the devices. At all surgeries Synapse Biomedical
staff were present to provide standard technical support. It is likely that the implantation procedures, which
followed the manufacturer’s recommendations, were comparable to those undertaken during the earlier
cohort study. Supporting this is the fact that the number of surgical complications was lower than previously
reported and there was no mortality within the 30-day perioperative period. All diaphragms were
stimulatable at surgery supporting our combined clinical and ultrasound assessment of residual phrenic
nerve function. No surgeries needed to be abandoned, as planned in the protocol, if on intraoperative
mapping of the diaphragm stimulation was not achievable. Following implantation the majority of patients
became regular users (mean daily use 6.2 hours) and titrated their use over the course of the study, in line
with the protocol and the manufacturer’s recommendations. There were six non-users in the NIV plus
pacing arm: five of these did not undergo surgery and one stopped pacing after pulling the wires out after
1 month. The overall survival analysis in the DiPALS trial was by intention to treat; however, if these
non-users were excluded, then the HR remained significant (HR 2.71, 95% CI 1.39 to 5.27).
Other confounders
Interventions proven to influence survival in ALS are riluzole, multidisciplinary team care and NIV.1,4–6
Riluzole use was equal across groups, as this was one of the inclusion criteria. NIV use was comparable
across both arms. All participating centres deliver multidisciplinary team care and were specialist centres for
treating patients with ALS and respiratory failure. The heath-care resource use indicated patients accessed
care in a similar manner, regardless of treatment group.
Limitations
Given that patients allocated DP underwent surgical intervention, it was unavoidable that participants were
unblinded as to the intervention. The study assessors were also unblinded to the intervention. The trial
statistician was unblinded, but withheld accumulating data from the study team. As the primary outcome
measure was objective (overall survival), the risk of bias is small, but there is an unavoidable risk of bias in
the subjective patient-reported secondary outcome measures. We considered inserting the DP devices in
the control group but not connecting them (sham pacing), to reduce the risk of bias and also to be able to
offer DP to control subjects at the end of the 12-month follow-up period, but concluded that implanting
control subjects appears less reasonable if one considerd a possible negative outcome. The effect of DP on
the ongoing use of NIV was a concern and we asked the question of whether or not patients stopped
using the NIV system, which has established survival benefit, in favour of the DP system. However, our
data show that this was not the case, with similar daily periods of NIV use across both groups.
There are imbalances between the treatment arms in our study, the most notable of which is that the NIV
plus pacing arm was slightly older. We have adjusted the HRs for this (and other) covariates, but also
propose that it is unlikely that such a small age difference would have a large impact on ALS survival.
Older age is negatively associated with survival, but less so within the ALS population, in which prognosis
is poor across all demographics; certainly, we are unaware of any previous work that has identified age as
having an impact that could explain a difference of this magnitude. Similar numbers of patients across
each group are reported to receive additional respiratory interventions. However, there are differences in
the frequency of cough assist use and breath stacking use, among those given devices, across the
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treatment groups. The effects of these differences are unknown but, again, are unlikely to explain the
observed poor survival in the NIV plus pacing group.
Developments since the completion of the Diaphragm Pacing in
patients with Amyotrophic Lateral Sclerosis trial
Recently, a second randomised trial [Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation
(RespiStimALS); NCT01583088] has also stopped early citing ‘absence of benefit [and] a statistically
significant excess mortality in the group of patients receiving active stimulation’.32,33 There are two notable
differences between this study and the DiPALS trial. First, DP implantation was carried out prior to
respiratory failure, with the primary end point being the time to requiring NIV. Second, all participants
underwent surgical procedure, but with the control group having a ‘sham’ procedure in which pacing was
not instigated until after NIV had started. The fact that an excess mortality was observed in the
intervention arm offers compelling evidence that pacing is actively harmful as opposed to surgery.
Subsequently, a third randomised study of DPS (NCT01938495) in the USA has suspended enrolment
pending further follow-up data from patients already randomised in the study.
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Chapter 7 Conclusions
Meaning of the study and implications for clinicians or
policy-makers
Diaphragmatic pacing should not be used as a routine treatment for all patients with ALS in respiratory
failure. We cannot exclude the possibility that it is beneficial in a subgroup of patients; however, this
should not be assumed. Our findings demonstrate that insertion of the NeuRX RA/4 DPS for pacing is
harmful when instigated at the point at which an individual with ALS develops respiratory failure. These
findings are further supported by a second RCT in which implanting was performed earlier in the disease
trajectory, which also stopped early because of excess mortality in the pacing arm (NCT01583088).32
A poor prognosis and the absence of curative therapy understandably encourage a ‘nothing to lose’
approach among patients and some clinicians alike, with an attendant lowering of the standards of
evidence required to adopt a new intervention. Our trial demonstrates the potential for harm that can arise
from adopting this approach.
Recommendations for future research
The findings of our trial, and also those of Gonzalez-Bermejo,32 are at odds with the promising survival
data presented in a previous cohort11 and, anecdotally, a small number of individual cases using
diaphragmatic pacing in our own clinics. Before any further study of DP in ALS is undertaken in the patient
population, we would encourage a meta-analysis of all current trial data on DPS in ALS. This may help to
identify whether or not there are any specific circumstances in which a patient may benefit from DP, such
as those with predominant upper motor neuron disease. In addition, the emerging findings within ALS
should prompt some consideration of the evidence for DP use among patients with spinal cord injury.
If any further studies take place in the future, they should include measures to understand the mechanism
by which harm or benefit occurs as a result of DP.
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Appendix 1 Changes to protocol
TABLE 16 Changes to protocol
Changes to protocol Progress report Date Approved by
Version 1
Version 1 (original submitted to REC) was amended
to version 2, on 3 August 2011, following comments
from the REC to incorporate the following:
Each site has experience in conducting research
in patients with ALS and their carers. These
healthcare professionals are trained in counselling
patients and carers at various stages of the
disease. Carers who experience any distress at any
time will be dealt with effectively
1 (dated
23 January 2012)
17 August 2011 NRES Committee
East of England –
Cambridge Central
Version 2
Version 2 was amended to version 3, on
24 August 2011, as part of a substantial amendment
(approved by REC on 20 September 2011), which
required some modification to the eligibility criteria.
There was also clarity required to ensure that the
Ionising Radiation section of the Integrated Research
Application System form was completed, as
participants require an ultrasound at screening and a
radiography postoperatively
1 (dated
23 January 2012)
20 September 2011 NRES Committee
East of England –
Cambridge Central
Version 3
Version 3 was amended to version 4, on
10 January 2012, as part of a minor amendment
(approved by the sponsors on 12 January 2012).
This was an update to clarify that NIV and DP
patients both receive their diaries on NIV initiation.
As this was just a minor change to the order of giving
the diary out, it was reviewed and approved by
the sponsor
2 (dated
13 July 2012)
20 January 2012 NRES Committee
East of England –
Cambridge Central
Version 4
Version 4 was amended to version 5, on
30 October 2012, with the following key changes:
1. The ‘trial treatment’ section of the protocol
(page 15) was amended from ‘NIV initiation to
occur within 1–2 weeks after randomisation’ to
‘NIV initiation will occur as per usual clinical
practice at the study site after randomisation’
2. Within ‘trial treatment’ the sentence ‘a provisional
date for implantation will be allocated at
randomisation (within 2–3 weeks)’ was amended
to ‘for those randomised to the DP arm, a
provisional date for implantation will be allocated
after randomisation. The date of surgery should
ideally be within 8 weeks of randomisation’
3. On page 16 of the protocol, the ‘participant flow’
diagram was amended. NIV and pacing arm boxes
were amended to take out ‘NIV initiation should
occur before DP insertion’
3 (dated
14 January 2013)
4 December 2012 NRES Committee
East of England –
Cambridge Central
continued
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TABLE 16 Changes to protocol (continued )
Changes to protocol Progress report Date Approved by
Version 5
Version 5 was amended to version 6,
on 21 May 2013, with the following changes:
1. Table 1 (page 13) was amended to clarify that
blood gases were required only in order to assess
eligibility for 4e of the eligibility criteria. As only
one of the inclusion criteria (4a–e) needs to be
fulfilled, blood gases only need to be performed if
a patient was to be entered onto the trial based
on 4e
2. On page 18 the sentences ‘A member of Synapse
will attend each procedure until sites become
competent with use of the device to manage
patients independently. The local site PI will be
responsible, after liaising with local site staff, for
deciding when site staff are competent in
performing the intervention without any input
from Synapse. The Surgeon at the site will
self-certify their competency to perform the
operation independently at this stage.’ were
added, as it is common practice for sites, once
competent, to not need Synapse assistance for
intervention 3
3. On page 19 the sentence ‘Pacing may be deferred
until the 1-week postoperative appointment to
allow patients to adjust to having the device fitted
in the immediate postoperative period.’ was
added. This was to match practice at all sites, as
was recognised that deffering pacing start enables
the patient to recover after their operation.
In addition to this, in the data collection table
(page 21) ‘post or e-mail’ was added to some of
the data collection tools to help optimise data
collection when it is difficult for patients to attend
in person
5 (dated
31 January 2014)
8 July 2013 NRES Committee
East of England –
Cambridge Central
Version 6
Version 6 was amended to version 7 on
7 October 2013. The protocol was amended to allow
respiratory tests up to 2 weeks pre consent, as was
standard practice
5 (dated
31 January 2014)
29 October 2013 NRES Committee
East of England –
Cambridge Central
Version 7
Version 7 was amended to version 7.1 on
5 November 2013. The data collection table was
amended to include data that would be collected
from NIV machines and diaries
5 (dated
31 January 2014)
15 November 2013 NRES Committee
East of England –
Cambridge Central
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TABLE 16 Changes to protocol (continued )
Changes to protocol Progress report Date Approved by
Version 8
Version 7.1 was amended to version 8, on
16 May 2014, with the following changes:
1. An additional sentence ‘** Data on any
respiratory tests routinely performed as part of the
participants management of ALS will be collected
over the participant’s involvement in the trial’ was
added to the protocol. This was to add the
collection of FVC/SNIP, etc., over the course of
12 months which would help determine which
participants are clinically deteriorating faster than
others in the study and to aid with the analysis
2. ‘NIV initiation will occur as per usual clinical
practice at the study site after consent has been
obtained.’ This was changed from ‘after
randomisation’ in the protocol. This was a
clarification in the protocol to allow participants in
the study to be given standard treatment, that is
NIV in each arm from after consent has been
obtained in the screening phase. As the screening
process could take a few weeks, this amendment
was necessary so as to prevent any standard
treatment being withheld from participants in
both arm as they clinically required it
3. Next to ALSFRS-R in the screening table, the text
‘and routine data’ was added to cover some
additional ALSFRS-R information we wished to
collect. This was routine clinical information
completed by the participants as part of their
standard care and would help determine the rate
of deterioration of participants in the trial
4. Figure 2 ‘screening and randomisation’ had the
label ‘*Note, NIV initiation can occur at any point
in the screening phase after consent has been
obtained’ added to clarify the point above
6 (dated
21 July 2014)
25 June 2014 NRES Committee
East of England –
Cambridge Central
NRES, National Research Ethics Service.
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Appendix 2 Trial summary
Screening evaluation
Eligibility confirmed
Patient allocated (n = 108) to trial arm via the web-based
randomisation system within 7 days of screening
Data collected at 2-, 3-, 6-, 9- and 12-month follow-up visits
Safety and AE data collected at each time point
Data cleaning, analysis and reporting
Standard respiratory
care – NIV (n = 54)
Standard respiratory care – NIV and DP
(n = 54)
Insertion of DP device and surgical evaluation
1-week post-operative follow-up
Qualitative interview of 12 patients and 12 carers at
1 and 6 months post implantation
Patient identified from clinic by site study team member and trial information sheet provided
Informed consent sought to undergo screening evaluation and participation in trial
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Appendix 3 Participant flow in each trial arm
Complete 
pre-operative
safety check
NIV arm
Patient attends clinic for
initiation of NIV – possible
overnight stay
Record baseline NIV settings,
NIV prescription given, type of
interface, humidification and
type of machine recorded
Take home patient diary
Pacing arm
Patient attends clinic/hospital for
initiation of NIV as per usual practice.
NIV initiation to occur before
 DP insertion
Take home patient diary
Patient attends hospital day before
planned operation. This may coincide
with NIV initiation inpatient stay
Site study team 
member reviews patient 
for new intercurrent illness 
that may affect safety 
for surgery
Withdrawal form
If patient fails
pre-operative
check due to FVC,
withdrawn from
treatment at this point
If patient fails 
pre-operative check owing 
to other complication, 
assess if/when can 
recall for surgery
If patient passes
pre-operative
check, perform surgery
Surgery
DP machine switched on
Research nurse rebook
patient in for surgery
Record
concomitant
medicines
and devices
throughout
Site study team
member book 
1-week 
appointment
Patient attend 1-week
follow-up at clinic
Qualitative group attend 
1-month post-implantation
qualitative interview 
(in clinic or home)
If patient on qualitative
study log, gain consent
fully from participant
and carer
Patient attend 2-month 
(post-randomisation) follow-up visit
• EQ-5D-3L
• Health-care resource use
• DPS and NIV use
• DPS parameters setting
• AE/side effects
Patients will normally 
be discharged
1–2 days after surgery
Take home 
patient carer manual
Collect any
SAE/safety
data
throughout
Complete
admission/
surgery form
Complete
discharge
evaluation
• FVC/SNIP
The carer will be asked to complete the EQ-5D-3L, the CBI and the qualitative interviews. Note that NIV initiation
can occur at any point in the screening phase after consent has been obtained. (continued )
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Patient attend 3-month 
(post-randomisation) follow-up visit
Qualitative group attend 
6-month post-implantation
qualitative interview 
(in clinic or home)
Patient attend 6-month 
(post-randomisation) follow-up visit
Patient attend 12-month 
(post-randomisation) follow-up visit
Patient attend 9-month 
(post-randomisation) follow-up visit
Record
concomitant
medicines
and devices
throughout
Research nurse collect
final survival status for
all participants
following last patient
last visit from
hospital/GP records
Study team
member action
Data collected 
at specific point
Qualitative 
participant flow
Trial participant flow
• SF-36
• SAQLI
• EQ-5D-3L
• CBI
• Health-care resource use
• DPS and NIV use
• DPS parameters setting
• AE/side effects
• SF-36
• SAQLI
• EQ-5D-3L
• CBI
• Health-care resource use
• DPS and NIV use
• DPS parameters setting
• AE/side effects
• EQ-5D-3L
• Health-care resource use
• DPS and NIV use
• DPS parameters setting
• AE/side effects
• SF-36
• SAQLI
• EQ-5D-3L
• CBI
• Health-care resource use
• DPS and NIV use
• DPS parameters setting
• AE/side effects
• Medical history and examination
The carer will be asked to complete the EQ-5D-3L, the CBI and the qualitative interviews. Note that NIV initiation
can occur at any point in the screening phase after consent has been obtained.
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Appendix 4 Screening and randomisation
Potential participant identified 
from neurology clinic or 
current patient list by site 
study team member (research
nurse, respiratory or 
neurology consultant)
Patient information sheet 
provided either:
Patient approached to gain 
informed consent either:
Read patient
information leaflet
Complete
screening forms and
baseline assessments
Complete
randomisation form,
enrolment log,
accrual spreadsheet
Complete informed
consent form
Patient gives informed consent for 
screening and study participation 
either:
Patient screened at this point by
site study team member
Site study 
team member will 
complete eligibility checks
If patient eligible randomise 
into the trial
within 7 days 
of screening
Participant informed by telephone 
within 7 days of which arm of the 
trial they are in by a study team
member and will be advised on 
when they will receive further 
information about NIV/surgery
Research nurse 
informs the participant’s 
GP – post GP letter
CJM and WB assess suitability 
for qualitative substudy 
and enter onto log
(1) Perform clinical test and 
assessment against eligibility criteria
• 12-lead ECG
• Arterial blood gases
• Blood tests [FBC, coagulation 
   (APTT and PT), CK, U and E,
   LFT and Ca]
• Respiratory insufficiency 
   (determined by one of – FVC/SNIP,
   supine VC, PaCO2 or O2
   desaturation overnight)
• Bilateral phrenic nerve function
(2) Complete baseline assessment
• EQ-5D-3L
• NIV use
• SF-36
• SAQLI
• CBI
• Medical history and examination
• ALSFRS-R
Study team
member action
Data collected 
at specific point
Qualitative 
participant flow
Trial participant flow
(1) at routine clinic appointment or
(2) posted before clinic appointment
(1) at next clinic appointment OR
(2) appointment made to attend 
      a screening clinic over the 
      telephone
(1) written consent 
(2) verbal consent
(3) consent given with communication
      aid 
When non-written consent given
an independent witness will sign
the consent form to verify
The carer will be asked to complete the EQ-5D-3L, the CBI and the qualitative interviews. Note that NIV initiation
can occur at any point in the screening phase after consent has been obtained. APTT, activated partial
thromboplastin time; Ca, calcium; CK, creatine kinase; ECG, electrocardiogram; FBC, full blood count; LFT, liver
function test; PT, prothrombin time; U and E, urea and electrolytes; VC, vital capacity.
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Appendix 5 Patient information sheet: patient
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Appendix 9 Consent form: patient
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Appendix 11 Consent form: patient qualitative
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Appendix 12 Consent form: carer qualitative
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Appendix 13 Statistical analysis plan
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DiPALS statistical analysis plan version 1.0 FINAL 
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Cardiovascular system  
Central nervous system  
Dermatological  
Gastro-intestinal  
Genito-urinary  
Infection of percutaneous endoscopic gastrostomy (PIG) or per-oral image 
guided gastrostomy (PEG) 
Insertion/removal of PIG/PEG 
Respiratory, further subdivided into 
Breathless – unclassified 
Chest infection 
Cough 
Infection 
Pneumothorax/Capnothorax 
Pulmonary Embolism 
Respiratory failure 
ALS symptoms 
NIV specific  
Pain  
Psychiatric 
Wire infection  
Wire problems  
Other 
DOI: 10.3310/hta20450 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 45
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McDermott et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
169
DiPALS statistical analysis plan version 2 FINAL including amendment 1 
APPENDIX 13
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Appendix 14 Stop pacing patient letter
(diaphragm pacing arm)
• 
• 
• 
• 
1. Left as they are. There is no evidence to suggest the presence of the wires is 
harmful. It is safe to leave them as they are. 
2. The wires can be cut as the leave the skin. You would have no wire visible but 
the inside part of the wires would be left in. 
3. You can be given a local anesthetic in the skin where the wires are located and 
the wires can be pulled out. 
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1. Left as they are. There is no evidence to suggest the presence of the wires is 
harmful. It is safe to leave them as they are. 
2. The wires can be cut as the leave the skin. You would have no wire visible but 
the inside part of the wires would be left in. 
3. You can be given a local anesthetic in the skin where the wires are located and 
the wires can be pulled out. 
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Appendix 15 Stop pacing patient letter
(non-invasive ventilation arm)
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Appendix 16 Stop pacing general practitioner
cover letter (diaphragm pacing arm)
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Appendix 17 Pacing discontinuation standard
operating procedure
1. The DMEC recommend that participants in the pacing arm stop pacing. 
2. All participants should remain to continue follow up until the last participant’s 
last visit (currently planned for mid-December 2014). 
3. On balance, it appears that pacing may be harmful to the study group that have 
had it implanted 
4. The group feel that it is unlikely that there will be any change in the data to 
suggest otherwise if the participants continued to pace. 
• Local study team to contact participants as soon as practicable by telephone/ 
home visit or clinic visit and inform them to stop pacing, using information 
contained in the Stop Pacing Letter to Patients (DP arm) V1 24Jun14.  If it is 
not possible to contact the participant via telephone, the letter should be posted 
or emailed.  
• The local study team should give the participants contact details of their 
emergency service so that if a deterioration is experienced on stopping pacing 
the participant knows who to contact 24 hours a day. There is a space on the 
letter to add your details. 
• The local study team should send to the patients GP: 
1) a copy of the “Stop Pacing Letter for Patients (DP arm)” V1 24Jun14  
2) a copy of the “Stop Pacing GP cover Letter” V1 24Jun14. 
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• The local study team should arrange to contact the patient by telephone/ home 
visit or clinic visit 24 hours and 1 week later following pacing cessation to 
review.  
• A discussion regarding patient’s wishes regarding wire removal should take 
place and the patient’s wishes be implemented.  
1. Disconnect device. Return Pacing unit. Internal and external wires left in situ. 
2. Disconnect device. Return pacing unit. Internal wires cut as leave body. 
3. Disconnect device. Return pacing unit. Wires pulled out under local 
anaesthetic. 
• Local study teams to contact participants via telephone/home visit/ clinic visit 
and give/send Stop Pacing (NIV arm) letter. 
• No action is required until full study results are available 
• Please record any change in condition due to stopping pacing as an adverse 
event and link to pacing withdrawal in the CRF 
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· Please complete Appendix 1 DP participant discontinuation checklist 
Date advice from DMEC to discontinue DP discussed 
 
  DATE: 
Option for pacing discontinuation chosen  
 
(mark appropriate box 
with X) 
1. Disconnect device. Return Pacing unit. Internal and external wires 
left in situ 
 
2. Disconnect device. Return pacing unit. Internal wires cut as leave 
body. 
 
 
Date wires cut: 
 
3. Disconnect device. Return pacing unit. Wires pulled out under local 
anaesthetic. 
 
 
Date wires removed: 
 
Other: (please provide information where the participant has not wished to choose one of the options 
above, complications from withdrawal of DP or wire procedures etc.) 
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Appendix 18 Qualitative interview topic guide
· Overview of the study  
· Details of funder  
· Overview of who is being selected for interview  
· Explanation of dissemination strategy and how the study will inform local 
services  
· Informal discussion  
· Views and opinions  
· No right or answers but interested in views and experiences  
· Recording of interviews  
· Information will remain anonymous  
· Review of information sheet with an opportunity to ask questions  
· Signing the consent form  
· What the surgery involved  
· Expectations of what the equipment would do  
· Size of equipment and wires involved  
· Any concerns they had prior to surgery  
· Expectation versus reality  
· If they were to tell someone else about the procedure what would they tell 
them  
· Fears, anxiety  
· Pain, discomfort  
· General anaesthetic 
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· Information provided  
· Who provided it and when  
· was any of the information provided before the surgery  
· Format – written or verbal 
· Was it easy to understand 
· Was it enough of was there anything else you wanted to know 
·  
· Support available at home  
· Did they know who and how to contact them  
· Any problems or complications using the equipment  
· Who manages the equipment, ensuring it is working properly, dealing with it 
at home  
· How easy is this to do and confidence to take on this role  
· Any early impacts on QoL apparent on  
· Individual  
· Carer  
· Family members  
· Friends  
· Overview of the study  
· Details of funder  
· Overview of who is being selected for interview  
· Explanation of dissemination strategy and how the study will inform local 
services  
· Informal discussion  
· Views and opinions  
· No right or answers but interested in views and experiences  
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· Recording of interviews  
· Information will remain anonymous  
· Review of information sheet with an opportunity to ask questions  
· Signing the consent form  
· Describe any changes that have occurred as a result of having the equipment 
fitted  
· Changes to behaviour both positive and negative  
· Does it interfere with certain activities such as dressing, washing etc  
· Is there anything that you dislike about the equipment  
· Explain what it’s like to use the equipment  
· How often and for what duration have you used this (overnight use)  
· Any adaptations made to how you were told to use it?  
· Barriers to using the equipment  
· Follow up at he clinic  
· Frequency of support and if any further support is required  
· Support from the ALS team  
· Any ways the support / information could be improved / adapted  
· Support from family and carer  
· In the past 6 months how have things changed  
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